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Background: The present review is part of the European Society of Clinical Microbiology and Infectious
Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on
the safety of targeted and biologic therapies.
Aims: To review, from an infectious diseases perspective, the safety proﬁle of therapies targeting
different intracellular signaling pathways and to suggest preventive recommendations.
Sources: Computer-based Medline searches with MeSH terms pertaining to each agent or therapeutic
family.
Content: Although BCR-ABL tyrosine kinase inhibitors modestly increase the overall risk of infection,
dasatinib has been associated with cytomegalovirus and hepatitis B virus reactivation. BRAF/MEK kinase
inhibitors do not signiﬁcantly affect infection susceptibility. The effect of Bruton tyrosine kinase in-
hibitors (ibrutinib) among patients with B-cell malignancies is difﬁcult to distinguish from that of pre-
vious immunosuppression. However, cases of Pneumocystis jirovecii pneumonia (PCP), invasive fungal
infection and progressive multifocal leukoencephalopathy have been occasionally reported. Because
phosphatidylinositol-3-kinase inhibitors (idelalisib) may predispose to opportunistic infections, anti-
Pneumocystis prophylaxis and prevention strategies for cytomegalovirus are recommended. No increased
rates of infection have been observed with venetoclax (antiapoptotic protein Bcl-2 inhibitor). Therapy
with Janus kinase inhibitors markedly increases the incidence of infection. Pretreatment screening for
chronic hepatitis B virus and latent tuberculosis infection must be performed, and anti-Pneumocystis
prophylaxis should be considered for patients with additional risk factors. Cancer patients receiving
mTOR inhibitors face an increased incidence of overall infection, especially those with additional risk
factors (prior therapies or delayed wound healing).of Hematology and Oncology, Klinikum Brandenburg, Hochstraße 29, Brandenburg an der Havel, 14770, Germany.
lberg.de (M. Reinwald).
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The present review is part of a larger effort launched by the
European Society of Clinical Microbiology and Infectious Diseases
(ESCMID) Study Group for Infections in Compromised Hosts
(ESGICH) and aims to analyse, from an infectious diseases
perspective, the safety proﬁle of biologic and targeted therapies. By
means of a set of unrestricted computer-based Medline searches
based on the MeSH terms appropriate for each agent or therapeutic
family, we identiﬁed literature pertaining to the subject. In addi-
tion, package information and boxed warning alerts from regula-
tory agencies (European Medicines Agency (EMA) and US Food and
Drug Administration (FDA)) were reviewed. Methodobiologic de-
tails are provided in the Introduction section of the present Sup-
plement issue [1]. For each agent or class of agents, a common
outline is offered: (a) summary of mechanism of action, approved
indications and most common off-label uses; (b) theoretically ex-
pected impact on the host's susceptibility to infection; (c) available
evidence emerging from the clinical use of that agent (i.e. ran-
domized clinical trials (RCTs), postmarketing studies, case series
and single case reports); and (d) suggested preventive and risk
minimization strategies. This section is devoted to review the risk
of infection entailed by the use of antineoplastic agents targeting
tyrosine kinases and other key signaling proteins. It should be
noted that the impact of antiangiogenic agents (such as monoclonal
antibodies against vascular endothelial growth factor (VEGF) and
its receptor, or VEGF tyrosine kinase inhibitors), antibodies against
the epidermal growth factor receptor and inhibitors of the intra-
cellular tyrosine kinase domain of cell-surface receptors of the ErbB
family (including the so-called multikinase inhibitors) has been
covered in another section of the issue [2].
Table 1 summarizes the development status, approved in-
dications and theoretical impact on infectious susceptibility of the
reviewed agents, whereas the suggested strategies to prevent such
complications are depicted in Table 2. It should be emphasized,
however, that in viewof the limited data available so far formany of
these agents, the provided recommendations are necessarily open
for constant modiﬁcations on the basis of ongoing and future
clinical observations. Increased awareness by clinicians is required
to identify emerging infections occurring in patients treated with
tyrosine kinase inhibitors, to report them promptly and to collect
information systematically within multicentre collaborative groups
in order not to miss uncommon but relevant events.
BCR-ABL tyrosine kinase inhibitors: imatinib, dasatinib,
nilotinib, bosutinib and ponatinib
Mechanism of action, approved indications and off-label uses
Chronic myeloid leukaemia (CML) is characterized by the (9; 22)
(q34; q11) translocation (cytogenetically visible as the Philadelphia
chromosome (Ph)), which gives rise to the breakpoint cluster re-
gion geneeAbelson murine leukaemia viral oncogene homologue 1
(BCR-ABL) fusion protein, a constitutively active tyrosine kinase
(TK) that induces cell survival and proliferation. Imatinib (Glivec or
Gleevec, Novartis Pharmaceuticals) was approved in 2001 as the
ﬁrst TK inhibitor for the treatment of Phþ CML. Imatinib binds tothe adenosine triphosphate (ATP)-binding pocket of the BCR-ABL
protein, thus preventing the kinase to become active. This agent
also blocks other TKs, such as the KIT (c-Kit) receptor, the stem-cell
factor receptor, the discoidin domain receptors (DDR1 and DDR2)
or the platelet-derived growth factor (PDGF) receptors (PDGFR-a
and -b) [3,4]. Imatinib is currently approved as ﬁrst-line therapy for
newly diagnosed Phþ CML in adults and children whose disease is
not suitable for haematopoietic stem-cell transplantation (HSCT),
or for those with disease in blast, accelerated or chronic phases
after failure of interferon (IFN)-a therapy. In addition, it is approved
for relapsed or refractory Phþ acute lymphoblastic leukaemia (ALL),
myelodysplastic or myeloproliferative diseases associated with
PDGFR gene rearrangements, aggressive systemic mastocytosis
without the D816V c-Kit mutation or with mutational status un-
known, hypereosinophilic syndrome and/or chronic eosinophilic
leukaemia, and unresectable, recurrent and/or metastatic derma-
toﬁbrosarcoma protuberans. Imatinib is the only ﬁrst-line targeted
therapy approved for patients with c-Kitepositive gastrointestinal
stromal tumours, both as adjuvant therapy after resection and in
the advanced/metastatic setting [3,4].
Dasatinib (Sprycel, Bristol-Myers Squibb) is a second-generation
multitargeted TK inhibitor that binds to the active and inactive
forms of the BCR-ABL kinase (as opposed to imatinib, which only
binds to the inactive state). It has been shown in vitro to exert a 300-
fold more potent inhibition than imatinib, being effective against
most imatinib-resistant BCR-ABL mutations. Dasatinib also targets
the SRC family kinases, c-Kit, PDGFR-a and -b, DDR1 and ephrin
receptors. This TK inhibitor is currently approved for newly diag-
nosed Phþ CML in chronic phase, as well as for patients with Phþ
CML in any phase or Phþ ALL and resistance or intolerance to prior
therapy, including imatinib [3,4].
Nilotinib (Tasigna, Novartis Pharmaceuticals) was 20 to 30
times more potent than imatinib in preclinical studies. Nilotinib
inhibits most imatinib-resistant BCR-ABL mutations, as well as c-
Kit, PDGFR, DDR1, VEGF and ephrin receptors. It is recommended
as ﬁrst-line treatment of newly diagnosed Phþ CML in chronic
phase and for patients with disease in chronic or accelerated
phases resistant to or intolerant to prior therapy, including ima-
tinib [3,4].
Bosutinib (Bosulif, Pﬁzer) is other dual-speciﬁc inhibitor of the
SRC and ABL kinase families that remains active against most BCR-
ABL resistance mutations, although it has minimal activity against
PDGFR and c-Kit. More potent than imatinib, bosutinib has been
approved for CML in patients who have developed resistance or
intolerance to previous therapies [3].
Ponatinib (Iclusig, Incyte Corporation) is a third-generation
multitargeted TK inhibitor that exhibits a unique carbon-carbon
triple bond allowing BCR-ABL kinase inhibition even in presence
of the T315I mutation, which alters the topology of the ATP-binding
region [3]. It is approved for patients with Phþ ALL or CML (in all
phases of disease) disease resistant or intolerant to prior TK
inhibitor-based therapies.
Expected impact on infection risk
Myelotoxicity is one of the most important adverse effects
associated with TK inhibitors, particularly among patients with
Table 1
Summary of reviewed inhibitors of intracellular signaling pathways, mode of action, approved indications and expected impact on immune response
Agent Pathway
affected
Approved indications
(regulatory agency)
Type of regimen Expected impact of immune
function
Imatinib, dasatinib, nilotinib,
bosutinib, ponatinib
BCR-ABL, c-Kyt,
other off-target
kinases
 Imatinib: Phþ CML and ALL,
MDS/MPD, hypereosinophilic
syndrome and/or chronic
eosinophilic leukaemia, GIST
(FDA and EMA), systemic
mastocytosis,
dermatoﬁbrosarcoma
protuberans (FDA only)
 Remaining agents: Phþ CML
Monotherapy or sequential
therapy
Neutropenia, reduced T-cell
activation and proliferation,
inhibition of CD34þ DCs
differentiation (imatinib)
Vemurafenib, dabrafenib,
encorafenib, trametinib,
cobimetinib, selumetinib,
Ras/Raf/
MEK/ERK
 All agents: unresectable or
metastatic melanoma (FDA
and EMA)
 Dabrafenib, trametinib: NSCLC
(EMA only)
 Selumetinib: thyroid
carcinoma (FDA and EMA)
Monotherapy, combination of
BRAF and MEK inhibitors
None
Ibrutinib, acalabrutinib Bruton tyrosine
kinase
 Ibrutinib: CLL, WM, mantle-cell
lymphoma (FDA and EMA),
marginal zone lymphoma (FDA
only)
 Acalabrutinib: mantle-cell
lymphoma (FDA only)
Monotherapy or combined with
rituximab and bendamustine
(CLL)
Inhibition of BCR signaling and B-
cell activation, HGG
Idelalisib, buparlisib,
rigosertib, duvelisib
Ras/PI3K/Akt/
mTOR
 Idelalisib: relapsed/refractory
CLL, del(17p) CLL, follicular
lymphoma
Monotherapy or combined with
rituximab or ofatumumab (CLL)
Inhibition of BCR signaling,
reduced chemokine production
Venetoclax Bcl-2  del(17p) CLL (FDA and EMA) Monotherapy Depletion of DCs, reduced IFN-a
production (animal model only)
Ruxolitinib, tofacitinib,
baricitinib
JAK/STAT  Ruxolitinib: polycythaemia
vera, myeloﬁbrosis (FDA and
EMA)
 Tofacitinib: rheumatoid
arthritis (FDA and EMA)
 Baricitinib: rheumatoid
arthritis (EMA only)
Monotherapy or combined with
methotrexate or nonbiologic
DMARDs (rheumatoid arthritis)
Inhibition of Th1 and Th17 cell
differentiation, inhibition of
cytokine secretion, reduction of
Tregs, impaired DCs function and
migration
Sirolimus, everolimus
temsirolimus,
Ras/PI3K/Akt/
mTOR
 Sirolimus: SOT (FDA and EMA)
 Everolimus: RCC, breast
carcinoma, neuroendocrine
tumours (FDA and EMA,
tuberous sclerosis-associated
tumours (FDA only)
 Temsirolimus: RCC (EMA and
FDA), mantle-cell lymphoma
(EMA only)
Monotherapy or combined with
other immunosuppressive agents
(SOT)
Impaired innate immunity,
reduced neutrophil migration,
reduced pro-inﬂammatory
cytokine production
ALL, acute lymphoblastic leukaemia; BCR, B-cell receptor; CCL, chronic lymphocytic leukaemia; CML, chronic myeloid leukaemia; DC, dendritic cell; del(17p), deletion of 17p;
DMARD, disease-modifying antirheumatic drug; EMA, European Medicines Agency; FDA, US Food and Drug Administration; GIST, gastrointestinal stromal tumour; HGG,
hypogammaglobulinaemia; MDS/MPD, myelodysplastic/myeloproliferative disease; NSCLC, nonesmall-cell lung carcinoma; Phþ, positive Philadelphia chromosome; RCC,
renal-cell carcinoma; SOT, solid organ transplantation; Treg, regulatory T-cell; WM, Waldenstr€om macroglobulinaemia.
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tropenia is expected to increase the risk of bacterial infection. It has
been demonstrated that TK inhibitors also inhibit CD4þ and CD8þ
T-cell proliferation in a dose-dependent manner through an off-
target kinase inhibition. By inhibiting LCK, a member of the SRC
family of TKs that phosphorylates the immunoreceptor tyrosine-
based activation motifs on the T-cell receptor, imatinib interferes
with T-cell activation and impairs cytomegalovirus (CMV)- and
Epstein-Barr virus (EBV)-speciﬁc CD8þ T-cell responses [6]. In vitro
studies have shown that imatinib also inhibits the differentiation
and function of CD34þ dendritic cells (DCs) [7] and CD4þCD25þ
regulatory T cells [8]. Both nilotinib and dasatinib have been asso-
ciated with an inhibition of CD8þ T-cell proliferation [9,10]. Similar
to imatinib, dasatinib inhibits the proliferation of CMV-speciﬁc
CD8þ T cells, as well as inﬂuenza matrix proteinespeciﬁc CD8þ T-
cell responses [10]. A recent study comparing the cellular and hu-
moral responses to inﬂuenza and pneumococcal vaccines in CML
patients on imatinib, dasatinib or nilotinib reported that TK in-
hibitors signiﬁcantly impair B-cell responses. TK inhibitor-treated
patients had signiﬁcantly lower antipneumococcal IgM titers andlower frequencies of peripheral blood IgM memory B cells after
vaccination compared to healthy controls [11].
Available clinical data
An initial trial that compared imatinib versus IFN-a plus low-
dose cytarabine for CML showed only a moderate increase in the
incidence of upper respiratory tract infection in the former group
[12]. A subsequent RCT involving 250 imatinib-treated patients
concluded that bacterial infection had a minor clinical impact and
that the occurrence of opportunistic infection was unusual [13].
Phase 2 trials evaluating imatinib and conventional chemotherapy
for Phþ ALL did not ﬁnd signiﬁcant differences in the risk of febrile
episodes or documented infections compared to that observedwith
conventional chemotherapy alone [14,15]. Nevertheless, reac-
tivation of hepatitis B virus (HBV) infection under imatinib treat-
ment for CML has been repeatedly reported [16e19]. HBV
reactivation was also described in two patients receiving imatinib
for nonhaematobiologic conditions [20,21]. Some of these cases
presented as fulminant hepatic failure, and at least two of them
Table 2
Summary of infection risks and suggested recommendations and management strategies
Agent Increased risk of
overall infection
Risk of OI Risk of PCP Risk of HBV
reactivation
Observations and recommendations
Imatinib, dasatinib,
nilotinib,
bosutinib, ponatinib
Modest IFI, HZ, tuberculosis, CMV
(particularly with dasatinib)
No Yes  Higher risk of infection with dasatinib (particularly after HSCT)
 Screening for chronic HBV infection before starting therapy
Antiviral prophylaxis while on therapy in HBsAg-positive patients
 Monitoring for HBV virus load in anti-HBc positive, HBsAg-negative
patients to assess eventual reactivation of occult HBV infection
 No expected beneﬁt from universal use of antibacterial, antiviral or
anti-Pneumocystis prophylaxis
Vemurafenib, dabrafenib,
encorafenib, trametinib,
cobimetinib selumetinib,
None No No No  No apparent increase in risk of infection
 Some of most common drug-related adverse effects (pyrexia, fatigue,
arthralgia and skin rash) may mimic ongoing infection
Ibrutinib, acalabrutinib Modest PCP, IFI, PML Yes (particularly in
presence of additional
risk factors)
No  Modest increase in risk of infection (contributing role of prior or
concurrent therapies or inherent immune defects)
 No expected beneﬁt from universal use of antibacterial or antifungal
prophylaxis
 Anti-Pneumocystis prophylaxis for CLL patients with additional risk
factors (e.g. purine analogues or high-dose corticosteroids)
 PML occasionally associated with use of ibrutinib
Idelalisib, buparlisib,
rigosertib, duvelisib
Major IFI, PCP, CMV Yes No  Increased risk of OIs and life-threatening adverse events (hepato-
toxicity, colitis and pneumonitis)
 Anti-Pneumocystis prophylaxis during course of therapy and for 2 to
6 months after discontinuation
 Monitoring for CMV infection during course of therapy in CMV-
seropositive patients or in presence of suspected CMV disease
 Discontinuation of therapy in presence of suspected pneumonitis or
grade 3/4 aminotransferase elevation or diarrhoea/colitis
Venetoclax None No No No  No apparent increase in risk of infection
Ruxolitinib, tofacitinib,
baricitinib
Major PCP, HZ, tuberculosis, CMV,
EBV, PML
Yes (particularly in
presence of additional
risk factors)
Yes  Increased risk of overall infection and OIs
 Screening for chronic HBV infection before starting therapy
 Antiviral prophylaxis while on therapy in HBsAg-positive patients
 Monitoring for HBV virus load in anti-HBc positive, HBsAg-negative
patients to assess eventual reactivation of occult HBV infection
 Screening for LTBI before starting treatment (followed by appropriate
therapy if needed)
 Anti-Pneumocystis prophylaxis in patients with additional risk factors
(e.g. high-dose corticosteroids)
Sirolimus, everolimus
temsirolimus,
Major HZ, tuberculosis No Yes  Increased risk of infection in cancer patients, especially in those with
additional risk factors (i.e. RCC, prior or concomitant cancer therapies,
delay in wound healing or aphthous stomatitis).
 Screening for chronic HBV infection and LTBI before starting therapy
(followed by appropriate therapy if needed)
 No expected beneﬁt from universal use of antibacterial, antiviral or
anti-Pneumocystis prophylaxis
Anti-HBc, hepatitis B core antibody; CCL, chronic lymphocytic leukaemia; CMV, cytomegalovirus; EBV, Epstein-Barr virus; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HSCT, haematopoietic stem-cell trans-
plantation; HZ, herpes zoster; IFI, invasive fungal infection; LTBI, latent tuberculous infection; OI, opportunistic infection; PCP, Pneumocystis jirovecii pneumonia; RCC, renal-cell carcinoma.
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medication [18,20]. Although the mechanism underlying this
complication is not completely understood, it appears to be asso-
ciated with the inhibition of the T-cell response (which would
allow intensive HBV replication) and the subsequent immune
reconstitution (which would trigger the immune-mediated injury
of infected hepatocytes) [18]. A retrospective analysis of 771 CML
patients treated with imatinib found a rate of about 2.0% for vari-
cella zoster virus de novo infection or reactivation (5.25 cases per
100 patient-years) [22]. Of note, varicella zoster virus infection was
associated with a longer course of CML and a more intensive prior
therapy, was not associated with disseminated forms and respon-
ded well to antiviral therapy. A case of herpes zoster (HZ) compli-
cating imatinib therapy in a patient with gastrointestinal stromal
tumours has been also reported [23], as have anecdotal examples of
disseminated EBV infection [24], pulmonary [25,26] and peritoneal
tuberculosis [27] and nocardiosis [28].
Data on nilotinib-related infection are scarce. Initial trials
comparing nilotinib with imatinib did not describe in detail the
occurrence of infectious complications [29,30]. A retrospective
multicentre analysis on 88 CML patients treated with nilotinib
found that seven of them (7.9%) developed infection (including one
case of perianal mycosis) [31]. A nilotinib-related HBV reactivation
has been recently reported [19].
A safety analysis of pooled data from dasatinib trials concluded
that serious infections were rare, with only one case of grade 3/4
opportunistic infection [32]. However, a retrospective analysis of 69
dasatinib-treated patients reported an incidence of infection of 51%
(with pneumonia and soft-tissue infections the most common
forms), with two cases of infection-attributable death. Only one
episode of proven invasive fungal infection (catheter-related
Candida krusei bloodstream infection) was observed. Patients with
infection were signiﬁcantly more likely to have ALL and to have
received high-dose corticosteroids. In multivariate analysis, treat-
ment with three or more cycles of dasatinib increased the risk of
infection [33]. A phase 3 study comparing two dosing regimens of
dasatinib for Phþ ALL (140 mg once daily vs. 70 mg twice daily)
reported an incidence of infection of 18% (8% for grade 3/4 events)
in the once-daily arm [34]. A recent study found that the use of
dasatinib in HSCT recipients to prevent or preemptively treat mo-
lecular relapse of Phþ haematobiologic malignancies signiﬁcantly
increased the risk of CMV reactivation during the ﬁrst post-
transplantation year (adjusted hazard ratio of 7.65 after controlling
for acute graft-versus-host disease) [35]. Further cases of CMV
disease (hepatitis and colitis) associated with the use of dasatinib
have been reported [36e39]. Finally, there have been sporadic re-
ports of PCP [40,41], HBV reaction [42], parvovirus B19 infection
and human herpesvirus 6 reactivation [43].
Data on the risk of infection with bosutinib and ponatinib are
still scarce. The BELA trial, which compared bosutinib and imatinib
for CML, reported similar rates of upper respiratory tract infection
(12% and 8%, respectively), with no cases of grade 3/4 infection
[44,45]. A phase 2 trial including 449 CML and ALL patients treated
with ponatinib reported six cases of infection-attributable death
(1.3%). Nevertheless, only two of them were deemed by the in-
vestigators to be related to ponatinib [46].
Data on the cumulative impact on infection susceptibility
resulting from the sequential use of different BCR-ABL tyrosine
kinase inhibitors in patients with CML and resistance or intolerance
to ﬁrst- or second-line agents are currently limited [47]. Most
studies, usually with small sample sizes, did not speciﬁcally report
the occurrence of infectious complications [48e50]. Only one
episode of infection (in the setting of grade 3/4 neutropenia) was
observed in a phase 1/2 trial with bosutinib in 118 patients previ-
ously treated with imatinib followed by dasatinib and/or nilotinib[51]. However, evaluation of cross-intolerance found that 22% of
patients with dasatinib intolerance experienced the same adverse
event on bosutinib as a grade 3/4 event, suggesting that the
development of deeper neutropenia might be expected with sec-
ond or third lines of therapy.Conclusions and suggested prevention strategies
 In view of available data, therapy with BCR-ABL TK inhibitors
implies amodest increase in the risk of infection, most likely due
to off-target inhibition of kinases involved in immune cells
functionality rather than direct inhibition of the BCR-ABL
signaling pathway.
 Dasatinib treatment appears to be associated with a higher rate
of infectious complications, particularly CMV infection and HBV
reactivation among HSCT recipients.
 Screening for chronic HBV infection should be performed before
starting treatment with BCR-ABL TK inhibitors. Antiviral pro-
phylaxis while on therapy should be offered to hepatitis B sur-
face antigen (HBsAg)-positive patients for preventing HBV
reactivation. In addition, monitoring for HBV virus load among
hepatitis B core antibody (anti-HBc)-positive, HBsAg-negative
patients could be indicated to assess the eventual reactivation
of occult HBV infection. Alternatively, hepatitis specialist referral
could be considered.
 No beneﬁt is expected from the universal use of antibacterial or
antiviral prophylaxis for patients receiving BCR-ABL TK in-
hibitors, although an individualized infection risk assessment
seems advisable. Anti-Pneumocystis prophylaxis should be
administered according to the general recommendations con-
tained in the current guidelines for noneHIV-infected patients
with haematobiologic conditions [52].BRAF and MEK kinase inhibitors: vemurafenib, dabrafenib,
trametinib, cobimetinib, selumetinib and encorafenib
Mechanism of action, approved indications and off-label uses
In the mitogen-activated protein kinase (MAPK) activating
pathway, Ras oncoproteins activate Raf, MEK and ERK kinases to
direct key cell proliferative and survival signals (Fig. 1). Activating
mutations of the B-type Raf kinase (BRAF) oncogene are present in
approximately 5% to 10% of all human malignancies and lead to
constitutive activation of the MAPK pathway. Nearly half of the
patients with advanced melanoma harbour the V600E mutation in
the BRAF gene; other, less common mutations include V600K or
V600R. Since the FDA approval of BRAF inhibitors for metastatic
melanoma in 2011 and the subsequent introduction of combina-
tion therapy with MEK inhibitors, the outcome of patients with
metastatic melanoma has dramatically changed. Survival has been
increased from months to years, with long-term control in a mi-
nority of patients [53]. Four compounds have been approved by
the FDA as monotherapy or combination therapy for metastatic
BRAF V600E/K-mutant melanoma. Vemurafenib (Zelboraf, Roche)
and dabrafenib (Taﬁnlar, GlaxoSmithKline) are BRAF inhibitors,
whereas trametinib (Mekinist, Novartis Pharmaceuticals) and
cobimetinib (Cotellic, Roche) are MEK1/2 inhibitors [53]. The ul-
timate mode of action of these agents is not entirely understood
but appears to involve stimulation of T-cell proliferation and
enhanced immune recognition of melanoma. In addition, the
combination of dabrafenib and trametinib has been recently
granted for nonesmall-cell lung carcinoma harbouring BRAF V600
mutations. Selumetinib and encorafenib are still in early phases of
development.
Growth factors and cytokines (IGF-1, VGEF...) 
PTEN 
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PIP3 
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Fig. 1. Key components of Ras/PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways. mTORC1 and mTORC2 complexes modulate cell cycle via effects on p21, p27 and cyclin D1
and E. mTORC1 complex phosphorylates 4E-BP1 and S6K1 activate protein translation. Important feedback mechanisms include inactivation of mTORC2 complex and inhibition of
Akt signaling by S6K1-mediated phosphorylation of Rictor and IRS1. Hypoxia, DNA damage and ATP deprivation activate TSC1/TSC2 to restrain mTORC1 and biosynthetic processes
in normal tissue. Oncogenic PI3K/PDK1 and Ras/MAPK signaling cooperate to reduce TSC1/TSC2 activity. PTEN, which normally restrains PI3K activity, is also frequently deleted or
inactivated in human cancer. mTOR inhibitors 3disrupt association between mTOR and Raptor. mTor, mammalian target of rapamycin; PI3K, phosphatidylinositol 3-kinase; PTEN,
phosphatase and tensin homologue on chromosome 10.
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While some of the antitumour effect of BRAF and MEK kinases
inhibition is believed to be mediated via the immune response (e.g.
natural killer cells), targeting these pathways does not result in any
apparent immunosuppression. Therefore, infection susceptibility is
not expected to be directly increased.
In fact, the contrary may be the case. The MEK signaling
pathway is involved in inﬂuenza virus replication, and combination
therapy with oseltamivir and MEK inhibitors showed in vitro syn-
ergistic activity [54]. The MEK pathway is also involved in the
regulation of FoxP3, a crucial transcription factor that controls
function and suppressive activity of regulatory T cells (Tregs).
Ex vivo MEK inhibition with trametinib in blood samples obtained
from HIV-infected patients with tuberculosis down-regulated
resting and activated Tregs and reduced the production of proin-
ﬂammatory cytokines in stimulated T cells, resulting in a net
improvement of the host's immune response by decreasing the
chronic proinﬂammatory state [55]. Trametinib suppresses
lipopolysaccharide-induced tumour necrosis factor a production
and endotoxin shock [56]. Further studies suggest that trametinib
may block Merkel-cell human polyomavirus (HPyV) infection in
ﬁbroblasts [57] or exert some antischistosomal activity [58]. Takentogether, these ﬁndings support a potential antimicrobial effect.
Moreover, this research line opens interesting prospects for the
eventual antiviral activity exerted by these agents and their added
value in certain neoplasms in whose pathogenesis oncogene vi-
ruses play an active role.
All available data hitherto are in line with the assumption that
BRAF and MEK kinases inhibition has no immunosuppressive
effects.
Available clinical data
The most common adverse effects in the landmark study
comparing vemurafenibwith dacarbazine formetastatic melanoma
with arthralgia, rash, fatigue, nausea, diarrhoea and cutaneous
squamous-cell carcinoma or keratoacanthoma [59]. Some of these
events may mimic an infectious aetiology but were attributed to a
direct effect by the drug in almost all cases. The high incidence of
squamous-cell carcinoma or keratoacanthoma, some of which are
mediated by human papillomaviruses and/or HPyV, prompted
additional research to clarify whether BRAF inhibition has a role in
viral activation and subsequent development of skin tumours. The
limited data available so far have been conﬂicting, with some
studies showing an association [60] and others failing to
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of the initial BRIM-3 trial [59] did not reveal any additional safety
issues regarding infectious events [62]. A similar lack of association
was reported in the comparator trial of cobimetinib with vemur-
afenib [63]. In a single-centre study, vemurafenib and dabrafenib
were compared for the effect on lymphocyte counts. Vemurafenib
therapy decreased lymphocyte counts and altered CD4þ T-cell
phenotype and function compared to dabrafenib [64]. In a further
analysis, the concomitant use of systemic corticosteroids and
vemurafenib was found to induce a more profound lymphopenia,
which was believed to contribute to the occurrence of infection in
some patients (with two of them dying from pneumonia). Unfor-
tunately, no further details were given as to the nature of the
pneumonia [65]. The occurrence of a sterile scrotal abscess was
reported in one patient receiving vemurafenib therapy, which was
believed to be related to the therapy [66].
Comparable to vemurafenib, dabrafenib therapy did not result
in any measurable increase in the risk of infection in large trials.
However, the more common adverse effects included skin-related
toxic effects, pyrexia and fatigue, again suggestive of an infectious
aetiology [67]. The most challenging issue may therefore be the
distinction between drug-induced toxicities and ongoing infection.
No association between the observed skin toxicity in dabrafenib-
treated patients and human papillomavirus infection was demon-
strated by immunohistochemical examination of skin samples [68].
However, the successful use of dabrafenib has been reported in a
patient with refractory hairy-cell leukaemia diagnosed in the pre-
vious month with invasive pulmonary aspergillosis [69].
In phase 2 and 3 studies with trametinib in combination with
dabrafenib, the occurrence of fever and chills was one of the most
common adverse effects observed, although it was directly attrib-
uted to the drug combination. No speciﬁc infection risk was found
[70e72].
Clinical data are still limited with selumetinib and cobimetinib,
but the safety proﬁle is expected to be in line with trametinib.
Selumetinib has been tested for recurrent or persistent endometrial
cancer but was not pursued further because of lack of efﬁcacy [73].
Encorafenib is still at an early stage of development, and no clinical
data exist so far.
Finally, the risk of infection was not increased with the use of
BRAF andMEK inhibitors in a meta-analysis [74] and in two reviews
on the management of most commonly observed toxicities [75,76].
Conclusions and suggested prevention strategies
 In view of available data, therapy with BRAF and MEK kinase
inhibitors does not increase the risk of infection. However, a
major clinical challenge is the mimicry of an ongoing infectious
complication by some of the most common drug-related
adverse effects observed with this therapy (i.e. pyrexia, fa-
tigue, arthralgia and rash).
 No speciﬁc prevention strategies are recommended for patients
receiving BRAF andMEK inhibitors, although continuous clinical
surveillance is advisable because the underlying mechanisms of
action are still poorly understood and rare infections may have
been missed, given the limited drug exposure so far.
Bruton tyrosine kinase inhibitors: ibrutinib and acalabrutinib
Mechanism of action, approved indications and off-label uses
Ibrutinib (Imbruvica, Janssen) is an inhibitor of the Bruton TK
(BTK), an important signaling molecule of the B-cell receptor (BCR)
and cytokine receptor pathways. The BCR pathway is implicated in
the pathogenesis of several B-cell malignancies, including chroniclymphocytic leukaemia (CLL), diffuse large B-cell lymphoma,
mature (peripheral) B-cell neoplasm small lymphocytic lymphoma
(SLL), follicular lymphoma, and mantle-cell lymphoma. Preclinical
studies have shown that ibrutinib inhibits numerous processes,
including ERK kinase signaling, nuclear factor kappa B DNA binding,
cytosineephosphateeguanineemediated CLL-cell proliferation,
and tumour-cell migration [77]. However, ibrutinib does not have
toxic effects on normal T cells, which distinguishes it from most
conventional therapy regimens used for CLL [77]. Ibrutinib as a
single agent is indicated for the treatment of adult patients with
previously untreated CLL or, in combination with bendamustine
and rituximab, for those that have received at least one prior
therapy. In addition, ibrutinib as a single agent has been approved
for relapsed or refractory mantle-cell lymphoma andWaldenstr€om
macroglobulinaemia in patients who have received at least one
prior therapy or as ﬁrst-line treatment for those deemed to have
disease unsuitable for chemoimmunotherapy. It was also recently
granted an accelerated FDA approval for the treatment of marginal
zone lymphoma.
Acalabrutinib (ACP-196, Acerta Pharma BV) is a second-
generation, more selective, irreversible BTK inhibitor with
improved pharmacologic features, including a more favourable
plasma exposure, rapid oral absorption, short half-life and absence
of irreversible targeting to alternative kinases. Compared to ibru-
tinib, which also targets ERK and other kinases, acalabrutinib exerts
a more selective action on BTK [75]. Acalabrutinib has obtained a
breakthrough therapy designation from the FDA for the treatment
of patients with mantle-cell lymphoma who have received at least
one prior therapy.
Expected impact on infection risk
Mutation of the BTK gene causes X-linked (or Bruton) agam-
maglobulinaemia. Patients with this primary immunodeﬁciency
exhibit a block in early B-cell maturation that prevents develop-
ment of antibody-producing cells, with the subsequent phenotype
consisting of severe, life-threatening bacterial infections [78].
Therefore, an impairment of humoral immunity eventually leading
to the development of hypogammaglobulinaemia could be a priori
expected among patients treated with BTK inhibitors. However,
some studies have reported an increase in peripheral blood B-cell
counts during the course of treatment with ibrutinib, as well as a
more rapid immune reconstitution and a signiﬁcantly lower rate of
infection compared to conventional chemotherapy. These ﬁndings
would suggest in fact that ibrutinib allows for a clinically mean-
ingful recovery of humoral immune function in patients with CLL
and other B-cell malignancies [79].
Available clinical data
The beneﬁt of ibrutinib for relapsed or refractory CLL have been
demonstrated in several prospective clinical trials [80e82]. In a
phase 1b-2 study to assess the safety and efﬁcacy of ibrutinib in
patients with relapsed or refractory CLL or SLL [81], long-term
therapy with this agent was associated with modest toxicity
because most adverse events were grade 1 or 2. Pneumonia
(occurring in ten patients, 12%) was the most common adverse
event of grade 3 or higher. The average rate of infection was 7.1 per
100 patient-months throughout the ﬁrst 6 months and 2.6 per 100
patient-months thereafter. In addition, ibrutinib caused a transient
increase in peripheral blood total lymphocyte counts [81]. In a
phase 3 study comparing ibrutinib versus ofatumumab (a CD20-
targeted monoclonal antibody) for relapsed or refractory CLL, the
rate of adverse events of grade 3 or higher (including diarrhoea and
new-onset atrial ﬁbrillation) was increased in the ibrutinib group.
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vs. 54%), although the occurrence of episodes of grade 3 or higher
was similar across both groups (24% vs. 22%). After upper respira-
tory tract infections, pneumonia and urinary tract infection (with
rates of about 10% among ibrutinib-treated patients) were the most
commonly observed syndromes [80]. In a phase 3 trial of ibrutinib
(vs. placebo) in combination with bendamustine and rituximab for
previously treated CLL or SLL, a safety proﬁle similar to that pre-
viously reported for each treatment arm individually was noted
(including the occurrence of neutropenia in more than 50% of pa-
tients) [82]. The overall proportion of patients with any adverse
event or grade 3/4 adverse event did not signiﬁcantly differ across
groups. Infection of any grade (70% in both groups) and of grade 3
or higher (29% in the ibrutinib group and 25% in the placebo group)
occurred similarly. A higher incidence of atrial ﬁbrillation was re-
ported, again in patients treated with ibrutinib [82]. Finally, the
safety of ibrutinib in a phase 3 trial for previously untreated older
patients with CLL or SLL (who often had clinically signiﬁcant
comorbidities) was consistent with that observed in previous re-
ports. Serious pneumonia and upper respiratory tract infection
occurred in 4% and 2% of patients, respectively [83].
The experience with ibrutinib for malignancies other than CLL
or SLL is also relevant [84e86]. Pneumonia of grade 3 or higher
was the most common infection among patients with relapsed or
refractory mantle-cell lymphoma and other types of non-
Hodgkin lymphoma treated with ibrutinib (with a rate of
approximately 6%) [84]. The safety proﬁle was favourable for
ibrutinib compared to temsirolimus in patients with relapsed or
refractory mantle-cell lymphoma [85]. In a study of previously
treated Waldenstrom macroglobulinaemia, one ibrutinib-treated
patient with IgA and IgG hypogammaglobulinaemia developed
streptococcal bacteraemia and infective endocarditis after a
dental procedure [86]. However, the occurrence of infections
deemed to be related to ibrutinib was uncommon because most
patients who developed infection had preexisting hypo-
gammaglobulinaemia [86].
Although the expected impact on T-cell function is low, oppor-
tunistic infections have been sporadically reported in patients
treated with ibrutinib, including cryptococcosis [87e89], PCP
[90,91], histoplasmosis [92], invasive aspergillosis [93,94] and
disseminated fusariosis [95]. Of note, cases of fatal progressive
multifocal leukoencephalopathy (PML) have been reported after
the use of ibrutinib in the context of multiple prior treatment lines,
including rituximab [96,97]. A recent literature review on the
occurrence of invasive fungal infections, including PCP, cryptococ-
cosis and invasive mould infection among patients treated with
ibrutinib has drawn attention to the plausible notion that this agent
could exert a deleterious off-target effect on the T cellemacrophage
axis. Moreover, the authors emphasized the interplay between
disease-related factors (i.e. status of underlying malignancy or co-
morbid conditions), environmental exposures to fungal conidia and
synergy with other immunosuppressive therapies in conferring an
increased susceptibility to fungal pathogens among patients
treated with ibrutinib and other tyrosine kinase inhibitors [98].
Because relapsed CLL patients often harbour additional risk factors
for PCP (such as multiple purine analog-based regimens or high-
dose corticosteroids) [52], some experts advocate for the admin-
istration of anti-Pneumocystis prophylaxis throughout the entire
course of ibrutinib therapy [99].
Safety data for acalabrutinib are still limited. In an uncontrolled
phase 1/2 trial including 61 patients with relapsed CLL, most
observed adverse events were of grade 1 or 2. Upper respiratory
tract infection occurred in 23% of patients, and only one death (due
to pneumonia) was observed during the course of the trial [100]. A
phase 3 study (ClinicalTrials.gov NCT02477696) has commenced inwhich acalabrutinib is being compared to ibrutinib for high-risk
patients with relapsed CLL.
Conclusions and suggested prevention strategies
 In view of available data, therapy with BTK inhibitors modestly
increases the risk of infection. However, it is difﬁcult to discern
the attributable risk because these agents are usually used in
combination with other immunosuppressive drugs in previ-
ously treated patients with B-cell malignancies that may be
associated with inherent immune defects.
 The occurrence of infection (including pneumonia, PCP and
invasive fungal infection) has been observed in ibrutinib-treated
patients, especially in the presence of neutropenia.
 Although no beneﬁt is expected from the universal use of
antibacterial or antifungal prophylaxis, patients receiving ibru-
tinib should be closely monitored for fever or neutropenia, and
appropriate anti-infective therapy should be instituted if
appropriate.
 Anti-Pneumocystis prophylaxis should be administered accord-
ing to current guidelines for noneHIV-infected patients with
haematobiologic conditions [52], especially in those with
relapsed or refractory CLL and additional risk factors for PCP (i.e.
alemtuzumab, purine analogue-based chemotherapy or pro-
longed high-dose corticosteroids).
 PML is a life-threatening complication occasionally associated
with the use of ibrutinib. The new onset of neurobiologic
symptoms in ibrutinib-treated patients should prompt clinical
suspicion and early treatment discontinuation, followed by
appropriate diagnostic assessment.
Phosphatidylinositol-3-kinase inhibitors: idelalisib,
Buparlisib, rigosertib and duvelisib
Mechanism of action, approved indications and off-label uses
The Ras/phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian
target of rapamycin (mTOR) pathway constitutes a critical signaling
pathway frequently altered in human cancer. The PI3K is a lipid
kinase that transmits signals from different surface receptors, such
as BCR, thereby regulating cellular growth, survival and migration
[101]. It comprises of a p85 regulatory and a p110 catalytic subunit
with four different isoforms (a, b, g and d). The PI3Kd signaling
pathways are frequently overexpressed in B-cell malignancies, thus
making its inhibition a promising therapeutic approach for CLL and
SLL [102]. Idelalisib (Zydelig, Gilead) is a potent small-molecule
PI3K inhibitor with highly selective activity against the d isoform
[103]. Idelalisib is currently indicated in combination with a CD20-
targeted monoclonal antibody (rituximab or ofatumumab) for the
treatment of adult patients with CLL after at least one prior therapy
or as ﬁrst-line treatment in the presence of 17p deletion (del(17p))
or TP53 mutations in patients not eligible for alternative thera-
peutic approaches. It is also indicated as monotherapy in patients
with refractory follicular lymphoma [104]. Buparlisib, rigosertib
and duvelisib are other PI3K inhibitors (some of them with addi-
tional action on the pololike kinase 1 (PLK-1) signaling pathway)
still in early phases of clinical development.
Expected impact on infection risk
In vitro, idelalisib signiﬁcantly reduced chemotaxis towards
CXCL12 and CXCL13, disrupted BCR signaling and interrupted
paracrine chemokine production by LLC cell lines [105]. In addition
to the role displayed by the PI3K/Akt/mTOR pathway in the survival
of cancer cells, its importance in the homeostasis of normal
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contributes to regulation of cytokine production by immune cells
[106], and therefore a risk of infection across all PI3K-targeted
drugs has been communicated [107].
Available clinical data
Data on the safety proﬁle of idelalisib mainly come from various
phase 1/2 studies and two larger phase 3 trials [104]. The most
frequently reported adverse drug reactions were rash, pyrexia,
diarrhoea, neutropenia, pneumonitis, hepatotoxicity and infection.
Serious infections describedwith idelalisib therapy include PCP and
CMV disease [104]. No infectious agents have been documented in
patients with idelalisib-related diarrhoea, and an autoreactive T-
cellemediated mechanism has been postulated [104]. The occur-
rence of fatal or serious pneumonitis not responding to conven-
tional antimicrobial therapy has been reported in about 4% of
idelalisib-treated patients (37/895) recruited across four RCTs,
compared to 1% (6/548) in the comparator arm [104].
In a phase 3 trial that assessed the efﬁcacy and safety of idela-
lisib plus with rituximab versus rituximab plus placebo in relapsed
CLL, idelalisib signiﬁcantly improved progression-free and overall
survival [108]. The most frequent serious adverse events in the
idelalisib and placebo groups were pneumonia (6% vs. 8%, respec-
tively), pyrexia (6% vs. 3%) and febrile neutropenia (5% vs. 6%). The
rates of PCP among idelalisib exposed and unexposed patients were
3% and 1% [108]. In a single-group phase 2 study for indolent
noneHodgkin lymphoma that had not responded to rituximab and
an alkylating agent or had resulted in early relapse, the most
commonly observed adverse events of grade 3 or higher were
neutropenia (27%), elevation of aminotransferase levels (13%),
diarrhoea/colitis (13%) and pneumonia (7%) [109]. Overall, this
regimen exhibited a favourable toxicity proﬁle, with low rates of
drug discontinuation due to adverse effects.
It is more difﬁcult to delineate the contributing role of idelalisib
to the occurrence of infection among CLL patients with disease
deemed unsuitable for standard chemotherapy; such patients are
frequently excluded from clinical trials as a result of the presence of
coexisting illnesses or relapsed markers. The most frequently
observed infections are respiratory and septic events. In many in-
stances, the causative agents were not documented, but both P.
jirovecii and CMV seem to be frequently involved. Nearly all epi-
sodes of PCP, including fatal ones, occurred in the absence of spe-
ciﬁc prophylaxis. A retrospective analysis including data from eight
clinical studies on CLL and SLL evaluated the clinical impact of PCP
in these populations (Sehn LH et al., “A retrospective analysis of
Pneumocystis jirovecii pneumonia infection in patients receiving
idelalisib in clinical trials,” paper presented at the American Society
of Hematology meeting, December 2016, San Diego, CA). Overall,
PCP occurred in 2.5% (35/1391) of idelalisib-treated patients and
0.25% (2/807) of control patients (mostly treated with CD20-
targeted and alkylating agents). Of note, only 1.2% (7/598) of pa-
tients receiving anti-Pneumocystis prophylaxis developed this
complication compared to 3.5% (28/793) of those without pro-
phylaxis. Post hoc analysis of peripheral blood lymphocyte counts
among idelalisib-treated patients with PCP or CMV infection sug-
gested that quantitative monitoring may not be useful to properly
assess the risk of these opportunistic infections; analysis also
suggested that the functional dysregulation of immune cells func-
tion may predispose the patient to such events, even in the absence
of signiﬁcant lymphopenia [110]. Finally, an open-label trial
comparing idelalisib with ofatumumab versus ofatumumab alone
in 261 patients with relapsed CLL conﬁrmed a higher incidence of
severe infection in the idelalisib group: pneumonia (13% vs. 10%),
sepsis (6% vs. 1%) and PCP (5% vs. 1%) [111]. Currently, the EMArecommends that anti-Pneumocystis prophylaxis should be
administered to all patients throughout idelalisib therapy and for a
period of 2 to 6 months after discontinuation, and that CMV
infection should be regularly monitored among CMV-seropositive
patients.
In March 2016, the EMA jointly analysed the results obtained
from three RCTs of idelalisib (with or without bendamustine and
rituximab) for previously untreated CLL or SLL. An increased risk of
death and higher incidence of serious adverse events (including
serious and/or fatal hepatotoxicity, colitis and pneumonitis) was
noted among subjects receiving idelalisib compared to the control
groups. For the EMA, these results indicate that idelalisib-related
toxicity is not outweighed by the expected beneﬁts, in view of
the favourable prognosis and low disease-related mortality of
previously untreated CLL patients. On the basis of these results, this
regulatory agency modiﬁed the prior terms of the marketing au-
thorizations for idelalisib and considered that such agents should
only be used in treatment-naive CLL patients with del(17p) if the
patients are not considered eligible for other therapies. In addition,
the FDA has required a speciﬁc warning about the risk of fatal and
serious idelalisib-related toxicities.
Conclusions and suggested prevention strategies
 In view of available data, therapy with idelalisib is associated
with an increased risk of opportunistic infections (including PCP
and CMV infection), and serious and occasionally fatal adverse
events (hepatotoxicity, colitis and pneumonitis).
 Anti-Pneumocystis prophylaxis is recommended for patients
receiving idelalisib throughout the entire course of therapy and
for 2 to 6 months after discontinuation.
 Regular monitoring for CMV infection during the course of
idelalisib therapy is advisable among CMV-seropositive patients
or in the presence of clinically suspected CMV disease.
 Idelalisib therapy must be discontinued upon occurrence of
suspected pneumonitis, grade 3/4 aminotransferase elevation
(>5 times the upper reference limit) or grade 3/4 diarrhoea/
colitis.
Antiapoptotic protein Bcl-2 inhibitors: venetoclax
Mechanism of action, approved indications and off-label uses
The constitutively elevated expression of the antiapoptotic
protein B-cell lymphoma 2 (Bcl-2), encoded by the BCL2 gene,
renders CLL cells resistant to apoptosis, resulting in the accumu-
lation of long-lived clonal lymphocytes that characterize the dis-
ease. Venetoclax (Venclyxto, AbbVie) is a highly selective inhibitor
of Bcl-2. In vitro, venetoclax induced apoptosis of primary CLL cells
and tumour cells that overexpressed BCL2, with minimal effects on
platelets [112]. Del(17p) is a cytogenetic abnormality leading to the
loss of the TP53 tumour suppressor gene that is found in 3% to 10%
of treatment-naive CLL patients and in up to 50% of those with
relapsed or refractory disease. Del(17p) is the most important poor
prognosis marker in the context of standard chemo-
immunotherapy; its presence is associated with lower treatment
response rate and shorter progression-free and overall survival
[113]. There are few effective therapeutic options for patients with
del(17p) CLL. Allogeneic HSCT is potentially curative but is only
suitable for selected patients. As previously mentioned, ibrutinib
monotherapy and idelalisib with rituximab are effective treatments
of greater duration than chemoimmunotherapy in these patients.
Venetoclax has been recently approved by the EMA and FDA (under
an accelerated procedure) for patients with del(17p) CLL who have
received at least one prior therapy.
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In addition to its role as regulators of apoptosis, the Bcl-2 family
of proteins also has other functions in nontumour cells, including
autophagy, calcium handling, mitochondrial dynamics and ener-
getics [114]. In a murine model of systemic erythematous lupus,
Bcl-2 antagonists selectively killed plasmacytoid DCs (which act as
antigen-presenting cells) and reduced IFN-a production [115].
Available clinical data
In a phase 1 study of oral venetoclax in a dose-escalation cohort
(from 150 mg to 1200 mg daily) and an expansion cohort (400 mg
daily) for relapsed or refractory CLL or SLL, the most important
adverse event was tumour lysis syndrome (occurring in 5.4% of
patients in the former group) [116]. A relevant feature in this study
was the occurrence of neutropenia (considered as grade 3/4 in 41%
of participants) and febrile neutropenia (in about 6%). Other serious
adverse events included pneumonia (4%), upper respiratory tract
infection (3%) and immune thrombocytopenia (3%) [116]. A phase 2
single-arm trial assessed the activity and safety of venetoclax
monotherapy in 107 patients with relapsed or refractory del(17p)
CLL [117]. Of note, the use of antimicrobial prophylaxis was not
mandatory. The majority of venetoclax-treated patients experi-
enced a reduction in absolute lymphocyte counts. The most com-
mon grade 3/4 adverse events were neutropenia (40.2%) and
infection (1.6%). Serious infections occurring in two or more pa-
tients were pneumonia (5.6%) and lower or upper respiratory tract
infection (1.9% each). One patient died from septic shock, and 12
(11.2%) developed infections requiring treatment interruption or
dose reduction [117].
In an internal integrated safety analysis of phase 1 and 2 trials
evaluating 330 patients with relapsed or refractory CLL who
received at least one dose of venetoclax, infections of any grade
occurred in approximately 70% of participants [118]. The most
common events were upper respiratory tract infection (23%),
pneumonia (11%) and nasopharyngitis (10%). Pneumonia was the
predominant grade 3/4 infection, and there were ﬁve cases of
infection-attributable death infection (due to septic shock and viral
pneumonia). Opportunistic infections occurred in 3.6% of patients
and included invasive aspergillosis, PCP, oral and esophageal
candidiasis, ocular toxoplasmosis, nocardiosis, herpes pharyngitis
and multidermatomal HZ [118]. Venetoclax is a CYP3A substrate,
and plasma levels are accordingly modiﬁed if coadministered with
CYP3A inducers or inhibitors [119].
Conclusions and suggested prevention strategies
 In view of (limited) available data, therapy with venetoclax
seems not to be associated with a meaningful increase in the
risk of infection, and no beneﬁt is expected from the use of
antibacterial, antiviral or anti-Pneumocystis prophylaxis.
 Continuous clinical surveillance in patients receiving venetoclax
is advisable because the underlying mechanisms are still poorly
understood, and rare infections may have beenmissed given the
limited drug exposure so far.
Janus kinase inhibitors: ruxolitinib, tofacitinib and baricitinib
Mechanism of action, approved indications and off-label uses
The family of Janus kinases (JAKs), which comprises four
different members (JAK1, JAK2, JAK3 and tyrosine kinase 2 (TyK2)),
plays a signiﬁcant role in haematopoiesis and immune-cell
signaling and differentiation. JAKs phosphorylate sites on thecytoplasmic tail of a variety of haematopoietic and inﬂammatory
cytokine receptors (i.e. erythropoietin or thrombopoietin re-
ceptors), thus effecting downstream targets via the signal trans-
ducer and activator of transcription (STAT) pathway. Different JAKs
or TyK2 exert differential effects. JAK1 and JAK2 deletions in murine
knockout models impair lymphoid and neural development and
erythropoiesis, respectively. Lack of TyK2 is associated with a
suboptimal interferon response [120]. Loss-of-function mutations
in the JAK3 gene lead to a clinical phenotype of severe combined
immunodeﬁciency [121e124]. Because JAK3 is downstream of a
variety of cytokine receptors involved in the inﬂammatory cascade,
such as interleukin-2, -4 or -21, pharmacobiologic inhibition of
these kinases was considered promising in treating autoimmune
diseases or even organ transplantation. In haematobiologic dis-
eases, the V617F activating mutation in the JAK2 gene has been
identiﬁed as one of the major hallmarks in the pathogenesis of
myeloproliferative neoplasms and has been identiﬁed in up to 95%
of patients with polycythaemia vera (PV) and in 50% to 60% of pa-
tients with myeloﬁbrosis and essential thrombocythaemia
[125,126]. Mutations in JAKs have also been identiﬁed in a variety of
other haematobiologic malignancies, such as acute myeloid
leukaemia and myelodysplastic syndromes [127].
Currently there are three EMA-approved JAK inhibitors. Rux-
olitinib (Jakavi, Novartis Pharmaceuticals) targets JAK1 and JAK2
and is approved for the treatment of patients with myeloﬁbrosis
[128] or PV (with disease resistant to or intolerant of hydroxyurea)
[129]. Tofacitinib (Xeljanz, Pﬁzer (formerly known as tasocitinib))
acts on JAK1, JAK2 and JAK3 (and to a lesser extent on TyK2) and is
indicated, in combination with methotrexate, for the treatment of
moderate to severe active rheumatoid arthritis (RA) in adult pa-
tients whose disease has not responded or is intolerant to disease-
modifying antirheumatic drugs (DMARDs) [130]. Baricitinib (Olu-
miant, Eli Lilly) is a selective and reversible inhibitor of JAK1 and
JAK2 that recently has been demonstrated to be superior to placebo
or adalimumab in refractory RA, thus receiving approval for this
condition [131]. In addition, JAK inhibitors are being evaluated for a
number of other indications, such as kidney transplantation
[132,133], psoriasis [134], graft-versus-host disease [135], re-
fractory leukaemia and solid malignancies [136].Expected impact on infection risk
Preclinical data show a distinct inﬂuence of JAK inhibitors on
several components of adaptive immunity. JAK inhibitors impair T-
cell function by decreasing the potential of producing proin-
ﬂammatory cytokines, and therefore Th1 and Th17 responses result
decreased both in vivo and in vitro [137]. Patients with myelopro-
liferative neoplasms treated with ruxolitinib showed a profound
reduction in Tregs and a silencing of T-cell helper cytokine secretion
[138]. Additionally, function and migration of DCs are impeded by
ruxolitinib, thus further aggravating immune system dysfunction
[139]. Lastly, ruxolitinib exposure led to a severe decrease in natural
killer cell counts, a phenomenon that was linked to an increase in
risk of infection [140]. Tofacitinib suppresses cytokine production,
proliferation and expansion of CD4þ Tcells in RA patients [141], and
it has been shown to modulate innate and adaptive immune re-
sponses by preventing the generation and differentiation of Th1
and Th17 cells [142].
Taken together, immunosuppressive properties of JAK inhibitors
are probably mediated by a combination of immune defects.
However, other factors (such as previous treatments, concurrent
immunosuppressive therapy, preexisting cytopenias, patient age
and comorbidities) most certainly contribute to modulate infection
susceptibility.
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For ruxolitinib, which is the agent with the longest time period
since approval, an increased risk of infection has been repeatedly
observed in clinical trials. In a pivotal trial that compared ruxolitinib
with best available therapy for myeloﬁbrosis patients, infections
were more frequently observed in the experimental arm [143],
including urinary tract infection (24.6%), pneumonia (13.1%), HZ
(11.5%), sepsis and septic shock (7.9%) and tuberculosis (1.0%) [144].
However, it should be stated that grade 3/4 neutropenia was
recognized in 7.1% and 2% of patients in the ruxolitinib and placebo
arms, respectively, thus confounding the immunosuppressive po-
tential of ruxolitinib. In addition, long-term follow-up did not show
an increase but rather a decrease in the incidence of infection, most
likely due to stabilization of the underlying disease [143]. Outside
the trial setting, recent real-life data from myeloﬁbrosis patients
treated with ruxolitinib identiﬁed several episodes of lethal infec-
tion [145], although the long-time evaluation of patients treated
within an expanded access program overall reported low incidence
and severity of infection [146]. For PV patients, data from a phase 3
trial indicate that ruxolitinib compared to standard therapy was
associated with an increased rate of overall (42% vs. 37%) and grade
3/4 infections (3.6% vs. 2.7%). In particular, HZ was more commonly
observed in ruxolitinib-treated patients (6% vs. 0) [129]. In patients
with relapsed acutemyeloid leukaemia treatedwith ruxolitinib, the
most common grade 3/4 nonhaematologic events consisted of
infection, especially pneumonia (57.7%, 15/26, of patients) [147].
Pneumonia was also much more frequent among patients with
metastatic pancreatic carcinoma receiving ruxolitinib compared to
placebo (plus capecitabine in both arms) [136]. Safety evaluation of
allogeneic HSCT recipients who had been treated with JAK in-
hibitors before transplantation also found atypical and opportu-
nistic infections to occur frequently, including CMV and EBV
reactivation (leading to posttransplantation lymphoproliferative
disorder in one case), BK HPyV-associated hemorrhagic cystitis and
invasive fungal infection [148]. In addition, case reports of severe
opportunistic infections in patients receiving ruxolitinib have been
repeatedly published, such as HBV reactivation (including occult
HBV infection reactivation in anti-HBcepositive, HBsAg-negative
patients) [149,150], Cryptococcus neoformans pneumonia [151],
PCP [152], bilateral Toxoplasma chorioretinitis [153], disseminated
tuberculosis [154] and PML [155].
Regarding the use of JAK inhibitors in rheumatologic conditions,
most data derive from tofacitinib. In a pivotal RCT, an increased rate
of serious infections was observed compared to placebo [156]. A
safety analysis of pooled data fromRA trials (covering approximately
4800 patients) found a signiﬁcant incidence of infection and
infection-related mortality with tocilizumab that, however, was
similar to that observed with other biologic agents. Age, diabetes,
prior corticosteroid therapy, low lymphocyte counts and tofacitinib
dose were independently linked to risk of serious infection [157]. A
recentmeta-analysis evaluating66RCTs and22 long-termextension
studies also illustrated a higher incidence of infection with tofaciti-
nib compared to placebo, although such risk was comparable to that
observedwithother biologicDMARDs [158]. Another recent analysis
evaluating the efﬁcacy and safety of tofacitinib in patients whose
disease had inadequate response to conventional synthetic or bio-
logic DMARDs conﬁrmed that patients receiving concurrent corti-
costeroid therapy had more serious infections, especially HZ [159].
A recent trial compared tofacitinib (5 or 10 mg daily) with eta-
nercept for the treatment of psoriasis. Rates of infection were
similar across study arms, with nasopharyngitis and upper respi-
ratory tract infections as the most common events [134]. Two
recently published trials in patients with psoriatic arthritis and
inadequate response to prior therapy with tumour necrosis factoraetargeted agents or conventional DMARDs, serious infections
(pneumonia and pyelonephritis) and HZ (including cases with
multidermatomal involvement) were more common with tofaciti-
nib than placebo [160] or adalimumab [161].
With regard to classic opportunistic infections, Winthrop et al.
[162] analysed phase 1/2 RCTs and long-term extension studies in
RA and identiﬁed 60 episodes among 5671 subjects. Tuberculosis
was the most common event and was associated with a higher
tofacitinib dose (tofacitinib 10 mg twice daily). Importantly, prior
treatment of latent tuberculosis infection with isoniazid seemed to
be protective. Other opportunistic infections included esophageal
candidiasis (nine cases), disseminated or multidermatomal HZ
(eight cases), CMV infection (six cases) and PCP (four cases) [162].
On the basis of the immunosuppressive properties of DMARDs
including tofacitinib, screening for viral hepatitis has been pro-
posed for patients receiving tofacitinib treatment, with prophylaxis
for those at medium or high risk of HBV reactivation [163].
Tofacitinib has been also compared to cyclosporine A in a phase 2b
trial for kidney transplant recipients [132]. Serious infections
(including CMV disease and EBV-associated posttransplantation lym-
phoproliferative disorder) were signiﬁcantly more common among
tofacitinib-treated patients. Pharmacokinetic analysis suggested an
exposure-dependent mechanism in infection susceptibility [164].
For the newest EMA-approved JAK inhibitor baricitinib, clinical
data on the risk of infectious complications can be only extracted
from phase 2 and 3 trials. In the initial study comparing different
doses with placebo, infectionwasmore frequent among baricitinib-
treated patients, although the rate of serious infections was com-
parable across groups (about 3%). Although HZ occurred in all three
arms, the largest numbers were seenwith baricitinib at the highest
analysed dose (4 mg) [165].
Conclusions and suggested prevention strategies
 In view of available data, therapy with JAK inhibitors is associ-
atedwith amarkedly increased risk of infection due to the direct
suppression of critical components of the immune system.
 Screening for chronic HBV infection should be performed before
initiating treatment with JAK inhibitors. Antiviral prophylaxis
while receiving therapy should be offered to HBsAg-positive
patients for preventing HBV reactivation. In addition, moni-
toring for HBV virus load among anti-HBc positive, HBsAg-
negative patients may be indicated to assess the eventual
reactivation of occult HBV infection. Alternatively, specialist
referral could be considered.
 Screening for latent tuberculosis infection may also be consid-
ered before starting treatment with JAK inhibitors (followed by
appropriate therapy if needed), as tuberculosis constitutes the
most common opportunistic infection observed.
 Clinicians caring for patients receiving JAK inhibitors should be
aware of the increased risk of overall and opportunistic infection
(including tuberculosis, PCP, HZ and invasive fungal infection),
especially in those with additional risk factors (i.e. prior or
concomitant corticosteroid therapy, low lymphocyte counts or
high-dose therapy with JAK inhibitors).
 In viewof (limited) available data, the administration of antiviral
and anti-Pneumocystis prophylaxis should be individualized
considered, especially in patients with additional risk factors.
mTOR inhibitors: sirolimus, temsirolimus and everolimus
Mechanism of action, approved indications and off-label uses
As previously mentioned, the Ras/PI3K/Akt/mTOR pathway
(Fig. 1) plays a crucial role in cell survival, growth and proliferation
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related kinase superfamily [167]. Two distinct mTOR complexes
have been identiﬁed, mTORC1 andmTORC2. The effects of mTOR on
growth, division and metabolism are largely attributable to
mTORC1, which is regulated by signals generated from growth
factors and cytokine receptors (such as human epidermal growth
factor receptor 2 (HER2), c-Kit, VEGF and PDGF) and by changes in
intracellular ATP content [168]. In addition, it is increasingly clear
that many cancer-promoting lesions activate the mTORC1 pathway
[169]. The key factor upstream of mTOR is PI3K, which, upon acti-
vation, is able to recruit Akt to the cell membrane that regulates cell
metabolism andmTOR activity. Phosphatase and tensin homologue
on chromosome 10 (PTEN) is a phosphatidylinositol-3-phosphatase
that negatively regulates this pathway and reverses the action of
PI3K [170]. The second mTOR-containing complex (mTORC2) is less
understood than mTORC1, but it seems to constitute a critical part
of a feedback loop in the PI3K/Akt pathway [171].
The mTORC1 complex regulates protein synthesis through two
downstream pathways, namely inactivation of the repressor of
mRNA translation 4E-BP1 (eukaryotic translation initiation factor
4E-binding protein) and activation of S6K1 (ribosomal S6 kinase 1)
that enhances mRNA translation. By phosphorylating the 4E-BP
family of proteins, mTORC1 represses their capacity to inhibit eIF4E
(eukaryotic translation initiation factor 4E), thus promoting protein
synthesis [172]. Akt is a positive regulator of mTORC1 that phos-
phorylates and thereby inhibits the heterodimeric tumour sup-
pressor complex (TSC)-1 (harmartin) and TSC2 (tuberin) by
removing its inhibitory effect on mTORC1 [168,173]. TSC1/TSC2
inhibits Rheb (Ras homologue enriched in brain), a positive regu-
lator of mTOR that acts downstream of TSC1/TSC2, PI3K and Akt.
Aberrant PI3K/mTOR activation is frequently observed in human
cancers [174]. The most common underlying mechanism is the loss
of PTEN gene expression due to deletion or inactivating mutations.
Up-regulation can also result from the activation of receptor TKs or
alterations of the different isoforms of PI3K [175].
The mTOR inhibitors comprise a unique drug class in possessing
both immunosuppressive and anticancer activity. Rapamycin
(Rapamune, Pﬁzer; also known as sirolimus) and its analogues, the
macrolides everolimus (Certican or Aﬁnitor, Novartis Pharmaceu-
ticals) and temsirolimus (Torisel, Pﬁzer), act by forming an allo-
steric inhibitory complex with their intracellular receptor, the
immunophilin FK506-binding protein (FKBP12), which binds a re-
gion in mTORC1 termed FRB (FKB12-rapamycin binding). Thus,
these agents inhibit mTORC1 kinase activity [176] (Fig. 1). In addi-
tion to direct effects on tumour cells, rapamycin also potently in-
hibits angiogenesis and endothelial cell proliferation [177,178].
The investigation of mTOR inhibitors as anticancer therapies
was aided by the fact that rapamycin (sirolimus) had been already
approved in 1998 to prevent acute rejection in solid organ trans-
plant (SOT) recipients. Several clinical trials have tested the efﬁcacy
of rapamycin and its analogues as anticancer therapy [179]. Ana-
lyses of neuroendocrine pancreatic tumours have shown alter-
ations in the mTOR pathway, with down-regulation of PTEN and
TSC2 observed in most cases [180]. The antineoplastic properties of
mTOR inhibitors were ﬁrst demonstrated for renal angiomyoli-
poma or pulmonary lymphangioleiomyomatosis in the setting of
tuberous sclerosis complex [181,182] and for Kaposi sarcoma
[183,184]. Experimental and clinical evidence also indicated a role
for the PI3K/mTOR pathway in the development of resistance in
patients with hormone receptorepositive breast cancer [185].
Everolimus has been approved by the FDA and EMA for the
treatment of advanced renal-cell carcinoma (RCC) after failure of
VEGF receptoretargeted therapies (sunitinib or sorafenib)
[186e189], advanced neuroendocrine pancreatic tumours [190],
advanced hormone receptorepositive HER2-negative breast cancer(in combination with exemestane) [191] and progressive
nonfunctional neuroendocrine gastrointestinal and lung tumours.
In addition, everolimus is FDA approved for subependymal giant-
cell astrocytoma and angiomyolipoma associated with tuberous
sclerosis [192]. Temsirolimus has been approved for advanced RCC.
In addition, there are promising results from a phase 3 trial for
refractory mantle-cell lymphoma [193]. However, even though
PTEN loss is frequently observed in sporadic glioma andmelanoma,
mTOR inhibitors have had only little efﬁcacy in these malignancies
[194e196]. In fact, the efﬁcacy of such agents has also been
disappointing in patients with metastatic breast cancer [197,198]
despite frequent PI3K activation [174].
Expected impact on infection susceptibility
In addition to the well-demonstrated direct inhibition on virus
replication exerted by mTOR inhibitors (particularly investigated
for CMV in the setting of SOT [199e201]), it should be highlighted
that mTORC1-mediated functions include both immunosuppres-
sive and immune-activating properties. The mTORC1 complex
promotes T-cell anergy, induces Treg expansion and inhibits
maturation of DC [202]. However, the use of mTOR inhibitors re-
sults in the enhancement of central and effector memory CD8þ T-
cell responses after vaccination in nonhuman primates [203]. The
role of mTOR in B-cell development and function has recently been
reviewed [204]. Relevant to the present review is the notion that
patients receiving mTOR inhibitors may have a hampered innate
immune response [205]. The migration of neutrophils to sites of
inﬂammation requires mTOR [206e208], as well as the production
of proinﬂammatory cytokines [206,209,210]. The defects in innate
immunity may be further compromised by the effect of mTOR in-
hibition on stromal cells, leading to impaired wound healing [211].
A relevant proportion of mTOR inhibitor-treated patients develop
stomatitis and pneumonitis, whichmay constitute an entry port for
pathogenic microorganisms [212]. The mTOR pathway has been
also implicated in neutrophil function, including formation of
extracellular traps that capture and kill microbes, in a process
involving the hypoxia-inducible factor 1a (HIF1a) pathway [213].
About 50% to 60% of cases or RCC exhibit loss of the von Hippel-
Lindau tumour suppressor, which encodes a negative regulator of
HIF1a [186]. Accordingly, an increased risk of respiratory and
genitourinary tract infections with everolimus or temsirolimus has
been observed in patients with RCC compared to those with other
carcinomas [214].
Available clinical data
Despite long-term experience with mTOR inhibitors in SOT re-
cipients, thewidespread use of these agents has been limited by the
relatively high discontinuation rates, reaching up to 20% to 30% of
participants in most transplantation trials [215e219]. These ob-
servations have posed a signiﬁcant challenge to the perception of
the efﬁcacy of mTOR inhibitors as immunosuppressive and/or
antineoplastic agents in relation to their tolerability. The most
common adverse effects attributed to mTOR inhibitors include
anaemia, thrombocytopenia and increased triglyceride and/or
cholesterol levels. Theoretically, therapeutic drug monitoring could
be helpful in preventing adverse events [220]. For everolimus,
however, a dose-dependent association has only been shown for
thrombocytopenia, not for leucopenia or hyperlipidaemia [221].
Aphthous stomatitis and diarrhoea are more frequently reported
than in patients treated with a calcineurin inhibitors and myco-
phenolic acid [222e224]. An infrequent but potentially life-
threatening adverse effect is noninfectious pneumonitis. This en-
tity is characterized by (nonspeciﬁc) inﬂammatory inﬁltrates in
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and bronchoalveolar lavage tests [225]. The incidence of pneumo-
nitis associated with sirolimus or everolimus has been reported to
be between 1% and 12% [226]. No deﬁnite risk factors have been
identiﬁed, and in case of pneumonitis related to a mTOR inhibitor
therapy, the drug class should be discontinued.
A systematic review of 12 RCTs reported an increased risk of
infectious complications associated with the use of high-dose
everolimus or temsirolimus in cancer patients [227]. Dosing stra-
tegies of mTOR inhibitors in cancer patients often differ from those
used in SOT recipients [228e232]. Of note, a higher risk of mortality
associated with the use of sirolimus has been found in a systemic
review based on individual patient data from 21 transplant trials
(involving about 6000 patients). This increased mortality rate was
not related to graft loss with return to dialysis but to cardiovascu-
lar- and infection-related deaths [233]. A recent meta-analysis
utilizing data from 12 phase 2 and 3 trials comparing everolimus
or temsirolimus versus placebo in cancer patients also reported a
signiﬁcantly higher risk of infection with mTOR inhibitors, with
incidences for all-grade and severe mTOR inhibitor-attributable
infection of 9.3% and 2.3%, respectively. The risk substantially var-
ied across different tumour types, being higher for RCC, lymphoma
and neuroendocrine tumours. There was no signiﬁcant difference
between everolimus and temsirolimus. Upper respiratory tract
infection, urinary tract infection and pneumonia were the pre-
dominant forms, with some examples of opportunistic infection
(i.e. tuberculosis and HZ) and HBV reactivation. Unfortunately,
speciﬁc information on the type of infection was not provided in
most of included trials [234]. Further case reports have highlighted
the risk of HBV reactivation in cancer patients receiving mTOR in-
hibitors [235,236].
Conclusions and suggested prevention strategies
 In viewof available data, therapywithmTOR inhibitors in cancer
patients is associated with an increased risk of infection, an
association that may be partially explained by the different
dosing strategies used in this population compared to SOT
recipients.
 Clinicians caring for patients receiving mTOR inhibitors should
be aware of the increased risk of overall infection, especially in
those with additional risk factors (i.e. certain speciﬁc malig-
nancies, prior or concomitant use of potent cancer therapies or
presence of drug-related delay in wound healing or aphthous
stomatitis).
 Screening for chronic (latent) infections, including HBV and
latent tuberculosis infection, may be advisable before initiating
treatment with mTOR inhibitors (followed by appropriate pro-
phylaxis or therapy if needed).
 No beneﬁt is expected from the universal use of antibacterial,
antiviral or anti-Pneumocystis prophylaxis for patients receiving
mTOR inhibitors, although it seems advisable to individualize
infection risk assessment.
Transparency declaration
Financial support was received from Plan Nacional de IþDþI
2013e2016 and Instituto de Salud Carlos III, Subdireccion General
de Redes y Centros de Investigacion Cooperativa, Spanish Ministry
of Economy and Competitiveness, Spanish Network for Research in
Infectious Diseases (REIPI RD16/0016/0002 and 0008), coﬁnanced
by the European Development Regional Fund (EDRF) ‘A way to
achieve Europe.’ MFR holds a clinical research contract ‘Juan Rodes’
(JR14/00036) from the Instituto de Salud Carlos III, Spanish Min-
istry of Economy and Competitiveness. MR received personal feesfrom Roche and Pﬁzer, and grants and personal fees from Gilead.
NM received research grants from Swiss National Science Foun-
dation. JMA received personal fees from Pﬁzer, Astellas and Merck.
All other authors report no conﬂicts of interest relevant to this
article.References
[1] Fernandez-Ruiz M, Meije Y, Manuel O, Akan H, Carratala J, Aguado JM, et al.
ESCMID Study Group for Infections in Compromised Hosts (ESGICH)
consensus document on the safety of targeted and biological therapies: an
infectious diseases perspective (introduction). Clin Microbiol Infect 2018;24:
S2e9.
[2] Aguilar-Company J, Fernandez-Ruiz M, García-Campelo R, Garrido-
Castro AC, Ruiz-Camps I. ESCMID Study Group for Infections in Compro-
mised Hosts (ESGICH) consensus document on the safety of targeted and
biologic therapies: an infectious diseases perspective (cell surface re-
ceptors and associated signaling pathways). Clin Microbiol Infect 2018;24:
S41e52.
[3] Jain P, Kantarjian H, Cortes J. Chronic myeloid leukemia: overview of new
agents and comparative analysis. Curr Treat Options Oncol 2013;14:
127e43.
[4] Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL in-
hibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma 2008;49:615e9.
[5] Deininger MW, Druker BJ. Speciﬁc targeted therapy of chronic myelogenous
leukemia with imatinib. Pharmacol Rev 2003;55:401e23.
[6] Seggewiss R, Lore K, Greiner E, Magnusson MK, Price DA, Douek DC, et al.
Imatinib inhibits T-cell receptoremediated T-cell proliferation and activation
in a dose-dependent manner. Blood 2005;105:2473e9.
[7] Appel S, Boehmler AM, Grunebach F, Muller MR, Rupf A, Weck MM, et al.
Imatinib mesylate affects the development and function of dendritic cells
generated from CD34þ peripheral blood progenitor cells. Blood 2004;103:
538e44.
[8] Chen J, Schmitt A, Giannopoulos K, Chen B, Rojewski M, Dohner H, et al.
Imatinib impairs the proliferation and function of CD4þCD25þ regulatory T
cells in a dose-dependent manner. Int J Oncol 2007;31:1133e9.
[9] Chen J, Schmitt A, Chen B, Rojewski M, Rubeler V, Fei F, et al. Nilotinib
hampers the proliferation and function of CD8þ T lymphocytes through in-
hibition of T cell receptor signalling. J Cell Mol Med 2008;12:2107e18.
[10] Fei F, Yu Y, Schmitt A, Rojewski MT, Chen B, Greiner J, et al. Dasatinib exerts
an immunosuppressive effect on CD8þ T cells speciﬁc for viral and leukemia
antigens. Exp Hematol 2008;36:1297e308.
[11] de Lavallade H, Khoder A, Hart M, Sarvaria A, Sekine T, Alsuliman A, et al.
Tyrosine kinase inhibitors impair B-cell immune responses in CML through
off-target inhibition of kinases important for cell signaling. Blood 2013;122:
227e38.
[12] O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al.
Imatinib compared with interferon and low-dose cytarabine for newly
diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:
994e1004.
[13] Breccia M, Girmenia C, Latagliata R, Loglisci G, Santopietro M, Federico V,
et al. Low incidence rate of opportunistic and viral infections during imatinib
treatment in chronic myeloid leukemia patients in early and late chronic
phase. Mediterr J Hematol Infect Dis 2011;3:e2011021.
[14] Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, et al. High
complete remission rate and promising outcome by combination of imatinib
and chemotherapy for newly diagnosed BCR-ABLepositive acute lympho-
blastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
J Clin Oncol 2006;24:460e6.
[15] Daver N, Thomas D, Ravandi F, Cortes J, Garris R, Jabbour E, et al. Final report
of a phase II study of imatinib mesylate with hyper-CVAD for the front-line
treatment of adult patients with Philadelphia chromosomeepositive acute
lymphoblastic leukemia. Haematologica 2015;100:653e61.
[16] Ikeda K, Shiga Y, Takahashi A, Kai T, Kimura H, Takeyama K, et al. Fatal
hepatitis B virus reactivation in a chronic myeloid leukemia patient during
imatinib mesylate treatment. Leuk Lymphoma 2006;47:155e7.
[17] Thia TJ, Tan HH, Chuah TH, ChowWC, Lui HF. Imatinib mesylateerelated fatal
acute hepatic failure in a patient with chronic myeloid leukaemia and
chronic hepatitis B infection. Singapore Med J 2008;49:e86e9.
[18] Kang BW, Lee SJ, Moon JH, Kim SN, Chae YS, Kim JG, et al. Chronic myeloid
leukemia patient manifesting fatal hepatitis B virus reactivation during
treatment with imatinib rescued by liver transplantation: case report and
literature review. Int J Hematol 2009;90:383e7.
[19] Lai GM, Yan SL, Chang CS, Tsai CY. Hepatitis B reactivation in chronic myeloid
leukemia patients receiving tyrosine kinase inhibitor. World J Gastroenterol
2013;19:1318e21.
[20] Walker EJ, Simko JP, Ko AH. Hepatitis B viral reactivation secondary to
imatinib treatment in a patient with gastrointestinal stromal tumor. Anti-
cancer Res 2014;34:3629e34.
[21] Lakhani S, Davidson L, Priebat DA, Sherker AH. Reactivation of chronic
hepatitis B infection related to imatinib mesylate therapy. Hepatol Int
2008;2:498e9.
M. Reinwald et al. / Clinical Microbiology and Infection 24 (2018) S53eS70S66[22] Mattiuzzi GN, Cortes JE, Talpaz M, Reuben J, Rios MB, Shan J, et al. Develop-
ment of varicella-zoster virus infection in patients with chronic myelogenous
leukemia treated with imatinib mesylate. Clin Cancer Res 2003;9:976e80.
[23] Durosinmi MA, Ogbe PO, Salawu L, Oyekunle AA. Herpes zoster complicating
imatinib mesylate for gastrointestinal stromal tumour. Singapore Med J
2007;48:e16e8.
[24] Leguay T, Foucaud C, Parrens M, Fitoussi O, Bouabdallah K, Belaud-
Rotureau MA, et al. EBV-positive lymphoproliferative disease with medul-
lary, splenic and hepatic inﬁltration after imatinib mesylate therapy for
chronic myeloid leukemia. Leukemia 2007;21:2208e10.
[25] Takashima M, Igaki N, Matsuda T, Ohyama M, Kanda S, Tamada F, et al.
Malignant gastrointestinal stromal tumor of the small intestine complicated
with pulmonary tuberculosis during treatment with imatinib mesylate.
Intern Med 2005;44:114e9.
[26] Daniels JM, Vonk-Noordegraaf A, Janssen JJ, Postmus PE, van Altena R.
Tuberculosis complicating imatinib treatment for chronic myeloid
leukaemia. Eur Respir J 2009;33:670e2.
[27] Senn L, Kovacsovics T, Tarr PE, Meylan P. Peritoneal tuberculosis after ima-
tinib therapy. Arch Intern Med 2009;169:312e3.
[28] Lin JT, Lee MY, Hsiao LT, Yang MH, Chao TC, Chen PM, et al. Pulmonary
nocardiosis in a patient with CML relapse undergoing imatinib therapy after
bone marrow transplantation. Ann Hematol 2004;83:444e6.
[29] Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib
versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med
2010;362:2251e9.
[30] Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW, et al.
Nilotinib vs. imatinib in patients with newly diagnosed Philadelphia
chromosomeepositive chronic myeloid leukemia in chronic phase: ENESTnd
3-year follow-up. Leukemia 2012;26:2197e203.
[31] Koren-Michowitz M, le Coutre P, Duyster J, Scheid C, Panayiotidis P,
Prejzner W, et al. Activity and tolerability of nilotinib: a retrospective
multicenter analysis of chronic myeloid leukemia patients who are imatinib
resistant or intolerant. Cancer 2010;116:4564e72.
[32] Reinwald M, Boch T, Hofmann WK, Buchheidt D. Risk of infectious compli-
cations in hemato-oncological patients treated with kinase inhibitors. Bio-
mark Insights 2015;10:55e68.
[33] Rodriguez GH, Ahmed SI, Al-akhrass F, Rallapalli V, Safdar A. Characteristics
of, and risk factors for, infections in patients with cancer treated with
dasatinib and a brief review of other complications. Leuk Lymphoma
2012;53:1530e5.
[34] Lilly MB, Ottmann OG, Shah NP, Larson RA, Reiffers JJ, Ehninger G, et al.
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-
positive acute lymphoblastic leukemia who failed imatinib: results from a
phase 3 study. Am J Hematol 2010;85:164e70.
[35] Prestes DP, Arbona E, Nevett-Fernandez A, Woolley AE, Ho VT, Koo S, et al.
Dasatinib use and risk of cytomegalovirus reactivation after allogeneic
hematopoietic-cell transplantation. Clin Infect Dis 2017;65:510e3.
[36] Davalos F, Chaucer B, Zafar W, Salman S, Nfonoyim J. Dasatinib-induced CMV
hepatitis in an immunocompetent patient: a rare complication of a common
drug. Transl Oncol 2016;9:248e50.
[37] Aldoss I, Gaal K, Al Malki MM, Ali H, Nakamura R, Forman SJ, et al. Dasatinib-
induced colitis after allogeneic stem cell transplantation for Philadelphia
chromosomeepositive acute lymphoblastic leukemia. Biol Blood Marrow
Transplant 2016;22:1900e3.
[38] Yassin MA, Nashwan AJ, Soliman AT, Yousif A, Moustafa A, AlBattah A, et al.
Cytomegalovirus-induced hemorrhagic colitis in a patient with chronic
myeloid leukemia (chronic phase) on dasatinib as an upfront therapy. Clin
Med Insights Case Rep 2015;8:77e81.
[39] Knoll BM, Seiter K. Infections in patients on BCR-ABL tyrosine kinase in-
hibitor therapy: cases and review of the literature. Infection 2018.
[40] Sillaber C, Herrmann H, Bennett K, Rix U, Baumgartner C, Bohm A, et al.
Immunosuppression and atypical infections in CML patients treated with
dasatinib at 140 mg daily. Eur J Clin Invest 2009;39:1098e109.
[41] Chang H, Hung YS, Chou WC. Pneumocystis jirovecii pneumonia in patients
receiving dasatinib treatment. Int J Infect Dis 2014;25:165e7.
[42] Ando T, Kojima K, Isoda H, Eguchi Y, Honda T, Ishigami M, et al. Reactivation
of resolved infection with the hepatitis B virus immune escape mutant
G145R during dasatinib treatment for chronic myeloid leukemia. Int J
Hematol 2015;102:379e82.
[43] Garcia-Munoz R, Galar A, Moreno C, Rodriguez-Otero P, Panizo-Morgado E,
Ponz-Sarvise M, et al. Parvovirus B19 acute infection and a reactivation of
cytomegalovirus and herpesvirus 6 in a chronic myeloid leukemia patient
during treatment with dasatinib (BMS-354825). Leuk Lymphoma 2007;48:
2461e4.
[44] Gambacorti-Passerini C, Cortes JE, Lipton JH, Dmoszynska A, Wong RS,
Rossiev V, et al. Safety of bosutinib versus imatinib in the phase 3 BELA trial
in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol
2014;89:947e53.
[45] Brummendorf TH, Cortes JE, de Souza CA, Guilhot F, Duvillie L, Pavlov D, et al.
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic
myeloid leukaemia: results from the 24-month follow-up of the BELA trial.
Br J Haematol 2015;168:69e81.
[46] Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al.
A phase 2 trial of ponatinib in Philadelphia chromosomeepositive leukemias.
N Engl J Med 2013;369:1783e96.[47] Jabbour E, Kantarjian H, Cortes J. Use of second- and third-generation tyro-
sine kinase inhibitors in the treatment of chronic myeloid leukemia: an
evolving treatment paradigm. Clin Lymphoma Myeloma Leuk 2015;15:
323e34.
[48] Garg RJ, Kantarjian H, O’Brien S, Quintas-Cardama A, Faderl S, Estrov Z, et al.
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase in-
hibitors: long-term follow-up. Blood 2009;114:4361e8.
[49] Giles FJ, Abruzzese E, Rosti G, Kim DW, Bhatia R, Bosly A, et al. Nilotinib is
active in chronic and accelerated phase chronic myeloid leukemia
following failure of imatinib and dasatinib therapy. Leukemia 2010;24:
1299e301.
[50] Ibrahim AR, Paliompeis C, Bua M, Milojkovic D, Szydlo R, Khorashad JS, et al.
Efﬁcacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients
with chronic myeloid leukemia in chronic phase who have failed 2 prior
lines of TKI therapy. Blood 2010;116:5497e500.
[51] Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M,
Kim DW, et al. Bosutinib is active in chronic phase chronic myeloid leukemia
after imatinib and dasatinib and/or nilotinib therapy failure. Blood 2012;119:
3403e12.
[52] Maertens J, Cesaro S, Maschmeyer G, Einsele H, Donnelly JP, Alanio A, et al.
ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients
with haematological malignancies and stem cell transplant recipients.
J Antimicrob Chemother 2016;71:2397e404.
[53] Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunother-
apies: optimizing outcomes in melanoma. Nat Rev Clin Oncol 2017.
[54] Haasbach E, Hartmayer C, Planz O. Combination of MEK inhibitors and
oseltamivir leads to synergistic antiviral effects after inﬂuenza A virus
infection in vitro. Antiviral Res 2013;98:319e24.
[55] Lieske NV, Tonby K, Kvale D, Dyrhol-Riise AM, Tasken K. Targeting tuber-
culosis and HIV infectionespeciﬁc regulatory T cells with MEK/ERK signaling
pathway inhibitors. PLoS One 2015;10:e0141903.
[56] Du SL, Yuan X, Zhan S, Tang LJ, Tong CY. Trametinib, a novel MEK kinase
inhibitor, suppresses lipopolysaccharide-induced tumor necrosis factor
(TNF)-alpha production and endotoxin shock. Biochem Biophys Res Com-
mun 2015;458:667e73.
[57] Liu W, Yang R, Payne AS, Schowalter RM, Spurgeon ME, Lambert PF, et al.
Identifying the target cells and mechanisms of merkel cell polyomavirus
infection. Cell Host Microbe 2016;19:775e87.
[58] Cowan N, Keiser J. Repurposing of anticancer drugs: in vitro and in vivo ac-
tivities against Schistosoma mansoni. Parasit Vectors 2015;8:417.
[59] Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al.
Improved survival with vemurafenib in melanoma with BRAF V600E muta-
tion. N Engl J Med 2011;364:2507e16.
[60] Cohen DN, Lawson SK, Shaver AC, Du L, Nguyen HP, He Q, et al. Contribution
of beta-HPV infection and UV damage to rapid-onset cutaneous squamous
cell carcinoma during BRAF-inhibition therapy. Clin Cancer Res 2015;21:
2624e34.
[61] Frouin E, Guillot B, Larrieux M, Tempier A, Boulle N, Foulongne V, et al.
Cutaneous epithelial tumors induced by vemurafenib involve the MAPK and
Pi3KCA pathways but not HPV nor HPyV viral infection. PLoS One 2014;9:
e110478.
[62] McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al.
Safety and efﬁcacy of vemurafenib in BRAF(V600E) and BRAF(V600K)
mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3,
randomised, open-label study. Lancet Oncol 2014;15:323e32.
[63] Ascierto PA, McArthur GA, Dreno B, Atkinson V, Liszkay G, Di Giacomo AM,
et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-
mutant melanoma (coBRIM): updated efﬁcacy results from a randomised,
double-blind, phase 3 trial. Lancet Oncol 2016;17:1248e60.
[64] Schilling B, Sondermann W, Zhao F, Griewank KG, Livingstone E, Sucker A,
et al. Differential inﬂuence of vemurafenib and dabrafenib on patients’
lymphocytes despite similar clinical efﬁcacy in melanoma. Ann Oncol
2014;25:747e53.
[65] Sondermann W, Griewank KG, Schilling B, Livingstone E, Leyh JC, Rompoti N,
et al. Corticosteroids augment BRAF inhibitor vemurafenib induced lym-
phopenia and risk of infection. PLoS One 2015;10:e0124590.
[66] Marsico JG, Rodriguez R, Muller J, Jorger M. Vemurafenib-related sterile
scrotal abscess in a patient with BRAFV600K-mutant advanced melanoma
mimicking distant metastasis. J Cancer Res Ther 2015;11:647.
[67] Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al.
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-
label, phase 3 randomised controlled trial. Lancet 2012;380:358e65.
[68] Anforth RM, Blumetti TC, Kefford RF, Sharma R, Scolyer RA, Kossard S, et al.
Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor
of mutant BRAF in patients with metastatic melanoma. Br J Dermatol
2012;167:1153e60.
[69] Vergote V, Dierickx D, Janssens A, Verhoef G, Tousseyn T, Vandenberghe P,
et al. Rapid and complete hematological response of refractory hairy cell
leukemia to the BRAF inhibitor dabrafenib. Ann Hematol 2014;93:2087e9.
[70] Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al.
Combined BRAF and MEK inhibition in melanoma with BRAF V600 muta-
tions. N Engl J Med 2012;367:1694e703.
[71] Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al.
Combined BRAF and MEK inhibition versus BRAF inhibition alone in mela-
noma. N Engl J Med 2014;371:1877e88.
M. Reinwald et al. / Clinical Microbiology and Infection 24 (2018) S53eS70 S67[72] Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A,
Stroiakovski D, et al. Improved overall survival in melanoma with combined
dabrafenib and trametinib. N Engl J Med 2015;372:30e9.
[73] Coleman RL, Sill MW, Thaker PH, Bender DP, Street D, McGuire WP, et al.
A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective
MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial
cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol
2015;138:30e5.
[74] Liu M, Yang X, Liu J, Zhao B, Cai W, Li Y, et al. Efﬁcacy and safety of BRAF
inhibition alone versus combined BRAF and MEK inhibition in melanoma: a
meta-analysis of randomized controlled trials. Oncotarget 2017;8:
32258e69.
[75] Cebollero A, Puertolas T, Pajares I, Calera L, Anton A. Comparative safety of
BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in ﬁrst-
line therapy for BRAF-mutated metastatic melanoma. Mol Clin Oncol
2016;5:458e62.
[76] Welsh SJ, Corrie PG. Management of BRAF and MEK inhibitor toxicities in
patients with metastatic melanoma. Ther Adv Med Oncol 2015;7:122e36.
[77] Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, et al.
Bruton tyrosine kinase represents a promising therapeutic target for treat-
ment of chronic lymphocytic leukemia and is effectively targeted by PCI-
32765. Blood 2011;117:6287e96.
[78] Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I, et al.
Deﬁcient expression of a B cell cytoplasmic tyrosine kinase in human X-
linked agammaglobulinemia. Cell 1993;72:279e90.
[79] Sun C, Tian X, Lee YS, Gunti S, Lipsky A, Herman SE, et al. Partial reconsti-
tution of humoral immunity and fewer infections in patients with chronic
lymphocytic leukemia treated with ibrutinib. Blood 2015;126:2213e9.
[80] Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib
versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl
J Med 2014;371:213e23.
[81] Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting
BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med
2013;369:32e42.
[82] Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, et al.
Ibrutinib combined with bendamustine and rituximab compared with pla-
cebo, bendamustine, and rituximab for previously treated chronic lympho-
cytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised,
double-blind, phase 3 study. Lancet Oncol 2016;17:200e11.
[83] Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as
initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med
2015;373:2425e37.
[84] Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with
ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med
2013;369:507e16.
[85] Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, et al.
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-
cell lymphoma: an international, randomised, open-label, phase 3 study.
Lancet 2016;387:770e8.
[86] Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. Ibrutinib in
previously treated Waldenstrom’s macroglobulinemia. N Engl J Med
2015;372:1430e40.
[87] Okamoto K, Proia LA, Demarais PL. Disseminated cryptococcal disease in a
patient with chronic lymphocytic leukemia on ibrutinib. Case Rep Infect Dis
2016;2016, 4642831.
[88] Stankowicz M, Banaszynski M, Crawford R. Cryptococcal infections in two
patients receiving ibrutinib therapy for chronic lymphocytic leukemia.
J Oncol Pharm Pract 2018. 1078155217752078.
[89] Messina JA, Maziarz EK, Spec A, Kontoyiannis DP, Perfect JR. Disseminated
cryptococcosis with brain involvement in patients with chronic lymphoid
malignancies on ibrutinib. Open Forum Infect Dis 2017;4:ofw261.
[90] Ahn IE, Jerussi T, Farooqui M, Tian X, Wiestner A, Gea-Banacloche J. Atypical
Pneumocystis jirovecii pneumonia in previously untreated patients with CLL
on single-agent ibrutinib. Blood 2016;128:1940e3.
[91] Lee R, Nayernama A, Jones SC, Wroblewski T, Waldron PE. Ibrutinib-associ-
ated Pneumocystis jirovecii pneumonia. Am J Hematol 2017.
[92] Pauff JM, Tillman BF, Talbott M, Satyanarayana G, Warner J. Integrated in-
fectious toxicity analysis of the BTK inhibitor ibrutinib. J Clin Oncol
2018;34(15 suppl):e19025.
[93] Arthurs B, Wunderle K, Hsu M, Kim S. Invasive aspergillosis related to
ibrutinib therapy for chronic lymphocytic leukemia. Respir Med Case Rep
2017;21:27e9.
[94] Gaye E, Le Bot A, Talarmin JP, Le Calloch R, Belaz S, Dupont M, et al. Cerebral
aspergillosis: an emerging opportunistic infection in patients receiving
ibrutinib for chronic lymphocytic leukemia? Med Mal Infect 2018 Feb 2.
https://doi.org/10.1016/j.medmal.2018.01.003 [Epub ahead of print].
[95] Chan TS, Au-Yeung R, Chim CS, Wong SC, Kwong YL. Disseminated fusarium
infection after ibrutinib therapy in chronic lymphocytic leukaemia. Ann
Hematol 2017;96:871e2.
[96] Lutz M, Schulze AB, Rebber E, Wiebe S, Zoubi T, Grauer OM, et al. Progressive
multifocal leukoencephalopathy after ibrutinib therapy for chronic lym-
phocytic leukemia. Cancer Res Treat 2017;49:548e52.
[97] Raisch DW, Raﬁ JA, Chen C, Bennett CL. Detection of cases of progressive
multifocal leukoencephalopathy associated with new biologicals andtargeted cancer therapies from the FDA’s adverse event reporting system.
Expert Opin Drug Saf 2016;15:1003e11.
[98] Chamilos G, Lionakis MS, Kontoyiannis DP. Call for action: invasive fungal
infections associated with ibrutinib and other small molecule kinase in-
hibitors targeting immune signaling pathways. Clin Infect Dis 2018;66:
140e8.
[99] Brown JR. How I treat CLL patients with ibrutinib. Blood 2018;131:379e86.
[100] Byrd JC, Harrington B, O’Brien S, Jones JA, Schuh A, Devereux S, et al. Aca-
labrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med
2016;374:323e32.
[101] Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differ-
entiation and activation. Nat Rev Immunol 2003;3:317e30.
[102] Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol
2006;18:77e82.
[103] Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ,
et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor
for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular
viability. Blood 2011;117:591e4.
[104] Zydelig (idelalisib). Summary of product characteristics. Gilead Sci. Available
at: https://www.medicines.org.uk/emc/product/3329/smpc.
[105] Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H,
Keating MJ, et al. The phosphoinositide 30-kinase delta inhibitor, CAL-101,
inhibits B-cell receptor signaling and chemokine networks in chronic lym-
phocytic leukemia. Blood 2011;118:3603e12.
[106] Xie S, Chen M, Yan B, He X, Chen X, Li D. Identiﬁcation of a role for the PI3K/
AKT/mTOR signaling pathway in innate immune cells. PLoS One 2014;9:
e94496.
[107] Raﬁi S, Roda D, Geuna E, Jimenez B, Rihawi K, Capelan M, et al. Higher risk of
infections with PI3K-AKT-mTOR pathway inhibitors in patients with
advanced solid tumors on phase I clinical trials. Clin Cancer Res 2015;21:
1869e76.
[108] Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al.
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J
Med 2014;370:997e1007.
[109] Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ,
et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent
lymphoma. N Engl J Med 2014;370:1008e18.
[110] Sharman JP, Salles GA, Jurczak W, Jones J, Owen CJ, Munugalavadla V, et al.
Temporal proﬁles of lymphocyte subsets and the correlation with infectious
events in idelalisib-treated patients. Blood 2016;128:5583.
[111] Jones JA, Robak T, Brown JR, Awan FT, Badoux X, Coutre S, et al. Efﬁcacy and
safety of idelalisib in combination with ofatumumab for previously treated
chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
Lancet Haematol 2017;4:e114e26.
[112] Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-
199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while
sparing platelets. Nat Med 2013;19:202e8.
[113] Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD, et al.
Bendamustine combined with rituximab in patients with relapsed and/or
refractory chronic lymphocytic leukemia: a multicenter phase II trial of the
German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011;29:
3559e66.
[114] Hardwick JM, Soane L. Multiple functions of BCL-2 family proteins. Cold
Spring Harb Perspect Biol 2013;5.
[115] Zhan Y, Carrington EM, Ko HJ, Vikstrom IB, Oon S, Zhang JG, et al. Bcl-2
antagonists kill plasmacytoid dendritic cells from lupus-prone mice and
dampen interferon-alpha production. Arthritis Rheumatol 2015;67:
797e808.
[116] Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al.
Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia.
N Engl J Med 2016;374:311e22.
[117] Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, et al.
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with
17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol
2016;17:768e78.
[118] Clinical Practice Guideline Forefoot Disorders Panel, Thomas JL, Blitch ELT,
Chaney DM, Dinucci KA, Eickmeier K, et al. Diagnosis and treatment of
forefoot disorders. Section 4. Tailor’s bunion. J Foot Ankle Surg 2009;48:
257e63.
[119] Agarwal SK, Salem AH, Danilov AV, Hu B, Puvvada S, Gutierrez M, et al. Effect
of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of ven-
etoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma. Br J Clin
Pharmacol 2017;83:846e54.
[120] Khwaja A. The role of Janus kinases in haemopoiesis and haematological
malignancy. Br J Haematol 2006;134:366e84.
[121] Russell SM, Tayebi N, Nakajima H, Riedy MC, Roberts JL, Aman MJ, et al.
Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid
development. Science 1995;270:797e800.
[122] Macchi P, Villa A, Giliani S, Sacco MG, Frattini A, Porta F, et al. Mutations of
Jak-3 gene in patients with autosomal severe combined immune deﬁciency
(SCID). Nature 1995;377:65e8.
[123] O’Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase in-
hibitors in autoimmune diseases. Ann Rheum Dis 2013;72(Suppl. 2).
ii111eii5.
M. Reinwald et al. / Clinical Microbiology and Infection 24 (2018) S53eS70S68[124] Casanova JL, Holland SM, Notarangelo LD. Inborn errors of human JAKs and
STATs. Immunity 2012;36:515e28.
[125] Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, et al. Widespread
occurrence of the JAK2 V617F mutation in chronic myeloproliferative dis-
orders. Blood 2005;106:2162e8.
[126] Staerk J, Constantinescu SN. The JAK-STAT pathway and hematopoietic stem
cells from the JAK2 V617F perspective. JAKSTAT 2012;1:184e90.
[127] Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E, et al. The
JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia
and acute myeloid leukemia, but not in acute lymphoblastic leukemia or
chronic lymphocytic leukemia. Blood 2005;106:3377e9.
[128] Harrison C, Kiladjian JJ, Al Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V,
et al. JAK inhibition with ruxolitinib versus best available therapy for
myeloﬁbrosis. N Engl J Med 2012;366:787e98.
[129] Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S,
Passamonti F, et al. Ruxolitinib versus standard therapy for the treatment of
polycythemia vera. N Engl J Med 2015;372:426e35.
[130] Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C,
Benda B, et al. Tofacitinib (CP-690,550) in combination with methotrexate in
patients with active rheumatoid arthritis with an inadequate response to
tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet
2013;381:451e60.
[131] Taylor PC, Keystone EC, van der HD, Weinblatt ME, Del Carmen ML, Reyes GJ,
et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis.
N Engl J Med 2017;376:652e62.
[132] Vincenti F, Tedesco SH, Busque S, O’Connell P, Friedewald J, Cibrik D, et al.
Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney
transplant patients: efﬁcacy, renal function and safety at 1 year. Am J
Transplant 2012;12:2446e56.
[133] Vincenti F, Silva HT, Busque S, O’Connell PJ, Russ G, Budde K, et al. Evaluation
of the effect of tofacitinib exposure on outcomes in kidney transplant pa-
tients. Am J Transplant 2015;15:1644e53.
[134] Bachelez H, van de Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH,
et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic
plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet
2015;386:552e61.
[135] Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK,
et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after
allogeneic stem cell transplantation: a multicenter survey. Leukemia
2015;29:2062e8.
[136] Hurwitz HI, Uppal N, Wagner SA, Bendell JC, Beck JT, Wade 3rd SM, et al.
Randomized, double-blind, phase II study of ruxolitinib or placebo in com-
bination with capecitabine in patients with metastatic pancreatic cancer
for whom therapy with gemcitabine has failed. J Clin Oncol 2015;33:
4039e47.
[137] Parampalli YS, Stubig T, Cornez I, Alchalby H, Schonberg K, Rudolph J, et al.
JAK1/2 inhibition impairs T cell function in vitro and in patients with
myeloproliferative neoplasms. Br J Haematol 2015;169:824e33.
[138] Keohane C, Kordasti S, Seidl T, Perez AP, Thomas NS, Harrison CN, et al. JAK
inhibition induces silencing of T helper cytokine secretion and a profound
reduction in T regulatory cells. Br J Haematol 2015;171:60e73.
[139] Heine A, Held SA, Daecke SN, Wallner S, Yajnanarayana SP, Kurts C, et al. The
JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo.
Blood 2013;122:1192e202.
[140] Schonberg K, Rudolph J, Vonnahme M, Parampalli YS, Cornez I, Hejazi M,
et al. JAK inhibition impairs NK cell function in myeloproliferative neo-
plasms. Cancer Res 2015;75:2187e99.
[141] Maeshima K, Yamaoka K, Kubo S, Nakano K, Iwata S, Saito K, et al. The JAK
inhibitor tofacitinib regulates synovitis through inhibition of interferon-
gamma and interleukin-17 production by human CD4þ T cells. Arthritis
Rheum 2012;64:1790e8.
[142] Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, et al. Modulation of
innate and adaptive immune responses by tofacitinib (CP-690,550).
J Immunol 2011;186:4234e43.
[143] Cervantes F, Vannucchi AM, Kiladjian JJ, Al Ali HK, Sirulnik A, Stalbovskaya V,
et al. Three-year efﬁcacy, safety, and survival ﬁndings from COMFORT-II, a
phase 3 study comparing ruxolitinib with best available therapy for
myeloﬁbrosis. Blood 2013;122:4047e53.
[144] Harrison CN, Vannucchi AM, Kiladjian JJ, Al Ali HK, Gisslinger H, Knoops L,
et al. Long-term ﬁndings from COMFORT-II, a phase 3 study of ruxolitinib vs.
best available therapy for myeloﬁbrosis. Leukemia 2016;30:1701e7.
[145] Jung CW, Shih LY, Xiao Z, Jie J, Hou HA, Du X, et al. Efﬁcacy and safety of
ruxolitinib in Asian patients with myeloﬁbrosis. Leuk Lymphoma 2015;56:
2067e74.
[146] Al Ali HK, Griesshammer M, le Coutre P, Waller CF, Liberati AM,
Schafhausen P, et al. Safety and efﬁcacy of ruxolitinib in an open-label,
multicenter, single-arm phase 3b expanded-access study in patients with
myeloﬁbrosis: a snapshot of 1144 patients in the JUMP trial. Haematologica
2016;101:1065e73.
[147] Pemmaraju N, Kantarjian H, Kadia T, Cortes J, Borthakur G, Newberry K, et al.
A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in
patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma
Myeloma Leuk 2015;15:171e6.
[148] Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, et al.
Outcomes of allogeneic hematopoietic cell transplantation in patients withmyeloﬁbrosis with prior exposure to Janus kinase 1/2 inhibitors. Biol Blood
Marrow Transplant 2016;22:432e40.
[149] Caocci G, Murgia F, Podda L, Solinas A, Atzeni S, La Nasa G. Reactivation of
hepatitis B virus infection following ruxolitinib treatment in a patient with
myeloﬁbrosis. Leukemia 2014;28:225e7.
[150] Perricone G, Vinci M, Pungolino E. Occult hepatitis B infection reactivation
after ruxolitinib therapy. Dig Liver Dis 2017;49:719.
[151] Wysham NG, Sullivan DR, Allada G. An opportunistic infection associated
with ruxolitinib, a novel Janus kinase 1,2 inhibitor. Chest 2013;143:1478e9.
[152] Lee SC, Feenstra J, Georghiou PR. Pneumocystis jirovecii pneumonitis
complicating ruxolitinib therapy. BMJ Case Rep 2014;2014.
[153] Goldberg RA, Reichel E, Oshry LJ. Bilateral toxoplasmosis retinitis associated
with ruxolitinib. N Engl J Med 2013;369:681e3.
[154] Colomba C, Rubino R, Siracusa L, Lalicata F, Trizzino M, Titone L, et al.
Disseminated tuberculosis in a patient treated with a JAK2 selective inhibi-
tor: a case report. BMC Res Notes 2012;5:552.
[155] Wathes R, Moule S, Milojkovic D. Progressive multifocal leukoencephalop-
athy associated with ruxolitinib. N Engl J Med 2013;369:197e8.
[156] Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD,
et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid
arthritis. N Engl J Med 2012;367:495e507.
[157] Cohen S, Radominski SC, Gomez-Reino JJ, Wang L, Krishnaswami S, Wood SP,
et al. Analysis of infections and all-cause mortality in phase II, phase III, and
long-term extension studies of tofacitinib in patients with rheumatoid
arthritis. Arthritis Rheumatol 2014;66:2924e37.
[158] Strand V, Ahadieh S, French J, Geier J, Krishnaswami S, Menon S, et al. Sys-
tematic review and meta-analysis of serious infections with tofacitinib and
biologic disease-modifying antirheumatic drug treatment in rheumatoid
arthritis clinical trials. Arthritis Res Ther 2015;17:362.
[159] Charles-Schoeman C, Burmester G, Nash P, Zerbini CA, Soma K, Kwok K, et al.
Efﬁcacy and safety of tofacitinib following inadequate response to conven-
tional synthetic or biological disease-modifying antirheumatic drugs. Ann
Rheum Dis 2016;75:1293e301.
[160] Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, et al.
Tofacitinib for psoriatic arthritis in patients with an inadequate response to
TNF inhibitors. N Engl J Med 2017;377:1525e36.
[161] Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F,
et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J
Med 2017;377:1537e50.
[162] Winthrop KL, Park SH, Gul A, Cardiel MH, Gomez-Reino JJ, Tanaka Y, et al.
Tuberculosis and other opportunistic infections in tofacitinib-treated pa-
tients with rheumatoid arthritis. Ann Rheum Dis 2016;75:1133e8.
[163] Singh JA, Saag KG, Bridges Jr SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015
American College of Rheumatology guideline for the treatment of rheuma-
toid arthritis. Arthritis Rheumatol 2016;68:1e26.
[164] Moore CA, Iasella CJ, Venkataramanan R, Lakkis FG, Smith RB, McDyer JF,
et al. Janus kinase inhibition for immunosuppression in solid organ trans-
plantation: is there a role in complex immunologic challenges? Hum
Immunol 2017;78:64e71.
[165] Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, et al.
Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med
2016;374:1243e52.
[166] Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges
and limitations. Nat Rev Cancer 2009;9:550e62.
[167] Jacinto E, Hall MN. Tor signalling in bugs, brain and brawn. Nat Rev Mol Cell
Biol 2003;4:117e26.
[168] Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H,
et al. mTOR interacts with raptor to form a nutrient-sensitive complex that
signals to the cell growth machinery. Cell 2002;110:163e75.
[169] Perl A. mTOR activation is a biomarker and a central pathway to autoim-
mune disorders, cancer, obesity, and aging. Ann N Y Acad Sci 2015;1346:
33e44.
[170] Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat
Rev Cancer 2004;4:335e48.
[171] Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. Identiﬁcation of the
tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a
target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 2002;10:
151e62.
[172] Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev
2004;18:1926e45.
[173] Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J. Tuberous sclerosis com-
plex gene products, Tuberin and Hamartin, control mTOR signaling by acting
as a GTPase-activating protein complex toward Rheb. Curr Biol 2003;13:
1259e68.
[174] Chiang GG, Abraham RT. Targeting the mTOR signaling network in cancer.
Trends Mol Med 2007;13:433e42.
[175] Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard
controlling cell growth. Biochem J 2008;412:179e90.
[176] Choi J, Chen J, Schreiber SL, Clardy J. Structure of the FKBP12-rapamycin
complex interacting with the binding domain of human FRAP. Science
1996;273:239e42.
[177] Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M,
et al. Rapamycin inhibits primary and metastatic tumor growth by anti-
angiogenesis: involvement of vascular endothelial growth factor. Nat Med
2002;8:128e35.
M. Reinwald et al. / Clinical Microbiology and Infection 24 (2018) S53eS70 S69[178] DeYoung MP, Horak P, Sofer A, Sgroi D, Ellisen LW. Hypoxia regulates TSC1/
2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3
shuttling. Genes Dev 2008;22:239e51.
[179] Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling
network for cancer therapy. J Clin Oncol 2009;27:2278e87.
[180] Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, et al.
Pancreatic endocrine tumors: expression proﬁling evidences a role for AKT-
mTOR pathway. J Clin Oncol 2010;28:245e55.
[181] Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, et al.
Sirolimus for angiomyolipoma in tuberous sclerosis complex or lym-
phangioleiomyomatosis. N Engl J Med 2008;358:140e51.
[182] Herry I, Neukirch C, Debray MP, Mignon F, Crestani B. Dramatic effect of
sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis
complex. Eur J Intern Med 2007;18:76e7.
[183] Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, et al. Siro-
limus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med
2005;352:1317e23.
[184] Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: a
successful treatment for posttransplantation Kaposi’s sarcoma. Trans-
plantation 2004;77:760e2.
[185] Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and anties-
trogen resistance in breast cancer. J Clin Oncol 2011;29:4452e61.
[186] Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin
Oncol 2004;22:4991e5004.
[187] Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Tem-
sirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J
Med 2007;356:2271e81.
[188] Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efﬁcacy
of everolimus in advanced renal cell carcinoma: a double-blind, randomised,
placebo-controlled phase III trial. Lancet 2008;372:449e56.
[189] Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Phase 3
trial of everolimus for metastatic renal cell carcinoma: ﬁnal results and
analysis of prognostic factors. Cancer 2010;116:4256e65.
[190] Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus
for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:
514e23.
[191] Baselga J, Campone M, Piccart M, Burris 3rd HA, Rugo HS, Sahmoud T, et al.
Everolimus in postmenopausal hormone-receptor-positive advanced breast
cancer. N Engl J Med 2012;366:520e9.
[192] Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, et al.
Efﬁcacy and safety of everolimus for subependymal giant cell astrocytomas
associated with tuberous sclerosis complex (EXIST-1): a multicentre, rand-
omised, placebo-controlled phase 3 trial. Lancet 2013;381:125e32.
[193] Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, et al.
Phase III study to evaluate temsirolimus compared with investigator’s choice
therapy for the treatment of relapsed or refractory mantle cell lymphoma.
J Clin Oncol 2009;27:3822e9.
[194] Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, et al. Phase II
trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a
North central cancer treatment group study. J Clin Oncol 2005;23:5294e304.
[195] Margolin K, Longmate J, Baratta T, Synold T, Christensen S, Weber J, et al. CCI-
779 in metastatic melanoma: a phase II trial of the California Cancer Con-
sortium. Cancer 2005;104:1045e8.
[196] Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, et al. Phase II
study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pre-
treated patients with locally advanced or metastatic breast cancer. J Clin
Oncol 2005;23:5314e22.
[197] An P, Mukherjee O, Chanda P, Yao L, Engelman CD, Huang CH, et al. The
challenge of detecting epistasis (G  G interactions). Genetic Analysis
Workshop 16. Genet Epidemiol 2009;33(Suppl. 1):S58e67.
[198] Fantus D, Thomson AW. Evolving perspectives of mTOR complexes in im-
munity and transplantation. Am J Transplant 2015;15:891e902.
[199] Havenith SH, Yong SL, van Donselaar-van der Pant KA, van Lier RA, ten
Berge IJ, Bemelman FJ. Everolimus-treated renal transplant recipients have a
more robust CMV-speciﬁc CD8þ T-cell response compared with cyclo-
sporine- or mycophenolate-treated patients. Transplantation 2013;95:
184e91.
[200] Pascual J, Royuela A, Fernandez AM, Herrero I, Delgado JF, Sole A, et al. Role
of mTOR inhibitors for the control of viral infection in solid organ transplant
recipients. Transpl Infect Dis 2016;18:819e31.
[201] Mallat SG, Tanios BY, Itani HS, Lotﬁ T, McMullan C, Gabardi S, et al. CMV and
BKPyV infections in renal transplant recipients receiving an mTOR
inhibitorebased regimen versus a cni-based regimen: a systematic review
and meta-analysis of randomized, controlled trials. Clin J Am Soc Nephrol
2017;12:1321e36.
[202] Pollizzi KN, Powell JD. Regulation of T cells by mTOR: the known knowns and
the known unknowns. Trends Immunol 2015;36:13e20.
[203] Turner AP, Shaffer VO, Araki K, Martens C, Turner PL, Gangappa S, et al.
Sirolimus enhances the magnitude and quality of viral-speciﬁc CD8þ T-cell
responses to vaccinia virus vaccination in rhesus macaques. Am J Transplant
2011;11:613e8.
[204] Limon JJ, Fruman DA. Akt and mTOR in B cell activation and differentiation.
Front Immunol 2012;3:228.[205] van Gelder T, ter Meulen CG, Hene R, Weimar W, Hoitsma A. Oral ulcers in
kidney transplant recipients treated with sirolimus and mycophenolate
mofetil. Transplantation 2003;75:788e91.
[206] Yang H, Wang X, Zhang Y, Liu H, Liao J, Shao K, et al. Modulation of TSC-
mTOR signaling on immune cells in immunity and autoimmunity. J Cell
Physiol 2014;229:17e26.
[207] Gomez-Cambronero J. Rapamycin inhibits GM-CSF-induced neutrophil
migration. FEBS Lett 2003;550:94e100.
[208] Gomez-Cambronero J, Horn J, Paul CC, Baumann MA. Granulocyte-macro-
phage colony-stimulating factor is a chemoattractant cytokine for human
neutrophils: involvement of the ribosomal p70 S6 kinase signaling pathway.
J Immunol 2003;171:6846e55.
[209] Lorne E, Zhao X, Zmijewski JW, Liu G, Park YJ, Tsuruta Y, et al. Participation of
mammalian target of rapamycin complex 1 in Toll-like receptor 2e and
4einduced neutrophil activation and acute lung injury. Am J Respir Cell Mol
Biol 2009;41:237e45.
[210] Liu L, Das S, Losert W, Parent CA. mTORC2 regulates neutrophil chemotaxis
in a cAMP- and RhoA-dependent fashion. Dev Cell 2010;19:845e57.
[211] Squarize CH, Castilho RM, Bugge TH, Gutkind JS. Accelerated wound healing
by mTOR activation in genetically deﬁned mouse models. PLoS One 2010;5:
e10643.
[212] Katholnig K, Linke M, Pham H, Hengstschlager M, Weichhart T. Immune
responses of macrophages and dendritic cells regulated by mTOR signalling.
Biochem Soc Trans 2013;41:927e33.
[213] Chiarini F, Evangelisti C, McCubrey JA, Martelli AM. Current treatment
strategies for inhibiting mTOR in cancer. Trends Pharmacol Sci 2015;36:
124e35.
[214] Kaymakcalan MD, Je Y, Sonpavde G, Galsky M, Nguyen PL, Heng DY, et al.
Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated
with mammalian target of rapamycin inhibitors. Br J Cancer 2013;108:
2478e84.
[215] Campbell SB, Walker R, Tai SS, Jiang Q, Russ GR. Randomized controlled trial
of sirolimus for renal transplant recipients at high risk for nonmelanoma
skin cancer. Am J Transplant 2012;12:1146e56.
[216] Euvrard S, Morelon E, Rostaing L, Gofﬁn E, Brocard A, Tromme I, et al.
Sirolimus and secondary skin-cancer prevention in kidney transplantation.
N Engl J Med 2012;367:329e39.
[217] Hoogendijk-van den Akker JM, Harden PN, Hoitsma AJ, Proby CM,
Wolterbeek R, Bouwes Bavinck JN, et al. Two-year randomized controlled
prospective trial converting treatment of stable renal transplant recipients
with cutaneous invasive squamous cell carcinomas to sirolimus. J Clin Oncol
2013;31:1317e23.
[218] Alberu J, Pascoe MD, Campistol JM, Schena FP, Rial Mdel C, Polinsky M, et al.
Lower malignancy rates in renal allograft recipients converted to sirolimus-
based, calcineurin inhibitor-free immunotherapy: 24-month results from the
CONVERT trial. Transplantation 2011;92:303e10.
[219] Campistol JM, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM, et al.
Sirolimus therapy after early cyclosporine withdrawal reduces the risk for
cancer in adult renal transplantation. J Am Soc Nephrol 2006;17:581e9.
[220] Kaplan B, Qazi Y, Wellen JR. Strategies for the management of adverse events
associated with mTOR inhibitors. Transplant Rev (Orlando) 2014;28:126e33.
[221] Budde K, Neumayer HH, Lehne G, Winkler M, Hauser IA, Lison A, et al.
Tolerability and steady-state pharmacokinetics of everolimus in mainte-
nance renal transplant patients. Nephrol Dial Transplant 2004;19:2606e14.
[222] Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, et al.
Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-
novo kidney transplants: an open-label, randomised, controlled trial. Lancet
2011;377:837e47.
[223] Bemelman FJ, de Fijter JW, Kers J, Meyer C, Peters-Sengers H, de Maar EF,
et al. Early conversion to prednisolone/everolimus as an alternative weaning
regimen associates with beneﬁcial renal transplant histology and function:
the randomized-controlled MECANO trial. Am J Transplant 2017;17:
1020e30.
[224] de Fijter JW, Holdaas H, Oyen O, Sanders JS, Sundar S, Bemelman FJ, et al.
Early conversion from calcineurin inhibitor- to everolimus-based therapy
following kidney transplantation: results of the randomized ELEVATE trial.
Am J Transplant 2017;17:1853e67.
[225] Pham PT, Pham PC, Danovitch GM, Ross DJ, Gritsch HA, Kendrick EA, et al.
Sirolimus-associated pulmonary toxicity. Transplantation 2004;77:1215e20.
[226] Molas-Ferrer G, Soy-Muner D, Anglada-Martinez H, Riu-Viladoms G, Este-
fanell-Tejero A, Ribas-Sala J. Interstitial pneumonitis as an adverse reaction
to mTOR inhibitors. Nefrologia 2013;33:297e300.
[227] Qi WX, Huang YJ, Yao Y, Shen Z, Min DL. Incidence and risk of treatment-
related mortality with mTOR inhibitors everolimus and temsirolimus in
cancer patients: a meta-analysis. PLoS One 2013;8:e65166.
[228] Knoll GA, Kokolo MB, Mallick R, Beck A, Buenaventura CD, Ducharme R, et al.
Effect of sirolimus on malignancy and survival after kidney transplantation:
systematic review and meta-analysis of individual patient data. BMJ
2014;349:g6679.
[229] Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J. Sirolimus
reduces the incidence of acute rejection episodes despite lower cyclosporine
doses in caucasian recipients of mismatched primary renal allografts: a
phase II trial. Rapamune Study Group. Transplantation 1999;68:1526e32.
M. Reinwald et al. / Clinical Microbiology and Infection 24 (2018) S53eS70S70[230] Kahan BD. Efﬁcacy of sirolimus compared with azathioprine for reduction of
acute renal allograft rejection: a randomised multicentre study. Rapamune
US Study Group. Lancet 2000;356:194e202.
[231] Flechner SM, Glyda M, Cockﬁeld S, Grinyo J, Legendre C, Russ G, et al. The
ORION study: comparison of two sirolimus-based regimens versus tacroli-
mus and mycophenolate mofetil in renal allograft recipients. Am J Transplant
2011;11:1633e44.
[232] Flechner SM, Gurkan A, Hartmann A, Legendre CM, Russ GR, Campistol JM,
et al. A randomized, open-label study of sirolimus versus cyclosporine in
primary de novo renal allograft recipients. Transplantation 2013;95:
1233e41.[233] Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R,
Brennan DC, et al. Conversion from calcineurin inhibitors to sirolimus
maintenance therapy in renal allograft recipients: 24-month efﬁcacy and
safety results from the CONVERT trial. Transplantation 2009;87:233e42.
[234] Garcia CA, Wu S. Attributable risk of infection to mTOR inhibitors everolimus
and temsirolimus in the treatment of cancer. Cancer Invest 2016;34:521e30.
[235] Mizuno S, Yamagishi Y, Ebinuma H, Nakamoto N, Katahira M, Sasaki A, et al.
Progressive liver failure induced by everolimus for renal cell carcinoma in a 58-
year-old male hepatitis B virus Carrier. Clin J Gastroenterol 2013;6:188e92.
[236] Sezgin Goksu S, Bilal S, Coskun HS. Hepatitis B reactivation related to ever-
olimus. World J Hepatol 2013;5:43e5.
